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ABSTRACT
CHARACTERIZATION OF HUMAN T-CELL LEUKEMIA VIRUS 1 REVERSE
TRANSCRIPTASE
Pinky Gundayao Agbuya 
Old Dominion University and Eastern Virginia Medical School. 2000 
Director: Dr. Laura K. Moen
Human T-cell leukemia virus 1 (HTLV-1) is a type C human retrovirus which has 
been the causative agent o f Adult T-cell leukemia. Replication o f the retrovirus requires 
a reverse transcriptase which converts the retroviral RNA into DNA which is later 
incorporated into the host's genome. Very little is known about the reverse transcriptase of 
HTLV-1. Researchers have attempted to purify HTLV-1 RT by isolating the enzyme from 
human cell lines. Because large amounts o f protein could not be produced by this isolation 
method, the reverse transcriptase cannot be fully characterized. In this research, a 
recombinant protein expressed in E. coli was purified, which has an apparent molecular 
weight consistent with that from virion-derived reverse transcriptase. This recombinant 
protein was purified to approximately 90% homogeneity by a two-step chromatographic 
process on phosphocellulose and sepharose CL-6B.
The reverse transcriptase of HTLV-1 is synthesized as a Gag-Pro-Pol precursor 
protein and undergoes proteolytic processing during maturation. By using sequence 
comparisons from a number of retroviral pol genes as well as information about the 
location o f the ribosomal frameshift, the location of the putative coding sequence for the 
enzyme has been identified. This information and PCR amplification was used to 
construct a clone, which spans a region o f the pro-pol junction o f HTLV-1. for 
overexpression in £. coli. The Pro-Pol protein was processed in vitro with a recombinant 
HTLV-1 protease to mimic the proteolytic processing o f the Gag-Pro-Pol precursor in the 
virion. SDS-PAGE analysis o f the cleavage sample revealed a 5.5 kDa fragment. This 
processed fragment o f the Pro-Pol protein was further treated with trypsin and analyzed 
by capillary LC-MS and MS/MS. Analysis o f the fragment by MS/MS revealed the N- 
terminal cleavage at LeuI57-Prol5S o f the pro ORF. These results confirm the authentic
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amino acid sequence of the reverse transcriptase of HTLV-l RT. The data reported here 
provides a basis for further investigation of the functional and structural aspects of 
protein-nucleic interaction of the enzyme.
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1CHAPTER I 
INTRODUCTION
Human T-cell Leukemia Virus 1 (HTLV-1) is a type C human retrovirus initially 
reported to be the causative agent of Adult T-cell leukemia (39-40. 96. 117. 136-138).
The virus was first isolated in 1980 by Poiesz et al. from a cell line derived from a patient 
with Adult T-cell Leukemia (ATL) (14, 35). ATL is a mature T-cell non-Hodgkin 
lymphoma with a leukemic phase characterized by circulating CD47CD25" T-cells (134). 
We now know that HTLV-1 infection has a much broader spectrum of disease 
manifestations including HTLV-1 associated myelopathy, tropical spastic paraparesis 
(HAM/TSP) (28. 38. 90. 100-101. 112, 120). uveitis (79) and an infectious dermatitis in 
children (60). Several inflammatory and immune-mediated conditions such as 
polymyositis, arthropathy. Sjogren’s syndrome, and facial nerve palsy have been 
associated with HTLV-1. although, a clear etiolgoical relationship has not been 
established (7.48, 128).
While the pathogeneses o f these diseases is unknown, all involve activated. 
HTLV-1 infected CD4' T-cells. The human T-cell lvmphotropic virus resides in and 
functionally alters immune cells o f central importance for immunoregulation. Thus, 
infection o f CD4' T-cells (immune cells) by HTLV-1 has several influences on the 
immune response: (1) interference with signaling pathways and transcriptional 
regulation: (2) activation o f resting T-cells which propagates the infection: (3) activation 
ofCD8~ cytotoxic T-lvmphocytes (CTLs) which alters cell death pathways in the host T- 
cell; and (4) induction of a strong antiviral immune response, which nonetheless is 
incapable o f  eradicating the infection (44).
EPIDEMIOLOGY OF HTLV-1
Worldwide, HTLV-1 infects between 11 and 20 million people. The infection is
The model for this dissertation is Archives o f  Biochemistry and Biophysics.
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endemic in Southern Japan, the Caribbean basin (10). parts of South America (4), parts 
of Africa (19, 143), the Middle East, the Pacific Melanesian Islands (150) and Papua New 
Guinea. The prevalence in these endemic populations ranges from 5-30% (88. 93. 141). 
The seroprevalence among low-risk populations, such as those o f the southern United 
States, is estimated to be 0.025% (70. 144). Patients who acquire HTLV-1 are at risk o f 
developing both infectious and noninfectious sequelae. Seropositive individuals have a 
0.1 to 1.0% risk o f developing HTLV-l associated myelopathy/tropical spastic 
paraparesis (HAM/TSP) (133). HAM is a chronic progressive inflammatory 
demyelinating myelopathy, often clinically confused with multiple sclerosis, that 
typically presents 10 to 30 years after infection with lower limb weakness, profound 
bladder dysfunction and minimal sensory loss.
Seropositive individuals have a 1 to 4% lifetime risk of developing ATL (133). 
Disease manifestations occur after a latent period and are classified by clinical and 
laboratory criteria as acute, chronic, lymphoma or smoldering ATL. Widespread or 
localized skin lesions such as large nodules, plaques, ulcers and a generalized papular 
rash are common. Immunosuppression is well documented, manifesting as bacterial and 
opportunistic infections which contribute to a poor prognosis (37, 120. 140).
Infectious dermatitis has been reported from several HTLV-1 endemic 
populations including Japan, Trinidad. Brazil, and Columbia. The disease is 
characterized by a severe exudative dermatitis o f the scalp, external ear and retroauricular 
aras, eyelid margins, paranasal skin. neck, axillae, and groin as well as generalized tine 
papular rash. The incidence and prevalence o f this disease are undefined, as is the 
pathogenesis (61. 151).
Idiopathic uveitis was observed to be very common in the HTLV-1 endemic areas 
of Kyushu. Japan, leading to speculation that HTLV-l infection might be the cause (79- 
80). Patients with HTLV-1 associated uveitis will often complain o f blurred or foggy 
vision and acute, sudden onset o f  floaters. Blurred vision is associated with acute onset 
o f mild inflammation in the vitreous body followed by mild iritis and retinal vasculitis.
HTLV-1 is, thus, the causative agent in clinical disorders affecting several organ 
systems. Excess morbidity and mortality have recently been reported among carriers (3)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
indicating that the full public-health impact o f HTLV-1 may be much greater than 
generally perceived.
MODES OF TRANSMISSION
The virus may be transmitted both horizontally through blood products, sexual 
contact and shared needles and vertically through breast milk, transplacentally, and 
intrapartum. O f these modes o f virus transmission, transfusion is perhaps the most 
efficient: the probability o f seroconversion in the recipient o f contaminated blood is 40- 
60% (74. 89). HTLV-1 transmission by blood products can lead to rapid development of 
HAM or TSP and has been seen within 6 months o f transmission (35). Today, routine 
blood-donor screening for antibodies to HTLV-1 is performed in the USA and other 
countries.
Most HTLV-1 infections are attributable to transmission from mother to child 
through prolonged breastfeeding or transmission by sexual contact later in life. Mother- 
to-child transmission of HTLV-1 occurs primarily through ingestion o f milk-borne 
lymphocytes (142) whereby transmission efficiency is dependent on duration of breast 
feeding and the presence of maternal antibodies to HTLV-1.
METHODS OF DETECTION
The identification o f HTLV-l by the detection o f antibodies in infected 
individuals is important because knowledge of HTLV-l seropositivity may help to 
prevent the transmission between sexual partners, as well as transmission from mother to 
child and blood transfusion. Detection o f antibodies to HTLV-1 is useful in establishing 
a diagnosis o f  ATL. HAM/TSP and other HTLV-1-associated diseases, and for screening 
o f blood donors and pregnant women. Methods to detect HTLV-1 antibodies include 
gelatin particle agglutination (PA), indirect immunofluorescence (IF), immunoperoxidase 
staining (IP), enzyme-linked immunosorbent assays (ELISA) with disrupted whole virus, 
synthetic peptides or recombinant proteins, radioimmunoprecipitation assay and Western 
blotting (73. 147).
ELISAs using whole virus lysate are the most commonly used screening assays 
for human sera or plasma in the United States and Europe. In Japan, the particle
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4agglutination assay is most commonly used for screening. Guidelines from the US Public 
Health Service and other international groups (78) recommend that newly identified 
seropositive individuals have additional blood collected for repeat testing to eliminate 
possible technical errors. IF. IP, radioimmunoprecipitation assay (RIPA) and Western 
Blotting (WB) assays are commonly used as supplementary assays to confirm specificity 
o f the antibodies to HTLV-1. The most common WB assays are constructed from whole 
virus lysate with the addition of recombinant envelope antigens and/or HTLV-1 and 
HTLV-2 specific envelope peptides to distinguish HTLV-1 to HTLV-2. HTLV-2 shares 
a 60% amino acid homology with HTLV-l (24. 121). Consequently, it is difficult to 
distinguish the two unless virus-specific reagents are used. TTiis distinction is important 
because HTLV-2 is less pathogenic than HTLV-1 (63).
Additionally, DNA analysis is used to diagnose ATL and other HTLV induced 
disease. Specifically, the polymerase chain reaction (PCR) has been used to identify 
type-specific proviral sequences in peripheral blood mononuclear cells from infected 
individuals to distinguish HTLV-1 from HTLV-2 and to detect DNA in tumor tissue and 
other biological specimens (95. 106).
Because HTLV-1 does not need a specific receptor for infection, it not only 
infects lymphocytes but also a variety o f other cells. After infection. HTLV-l randomly 
integrates its provirus into the chromosomal DNA. Since ATL cells show clonal 
proliferation in HTLV-1 infected T-lymphocytes. the demonstration o f clonal integration 
o f the HTLV-1 provirus is essential for the diagnosis of ATL (148). Southern blot 
analysis is used to identify the clonal proliferation of HTLV-1 cells. However. Southern 
blot analysis requires 5% infected cells for detection (147). The PCR method is much 
more sensitive, yet. it cannot distinguish whether HTLV-1 infected cells proliferate 
monocionally or polyclonally. Inverse PCR (IPCR) enables the identification of 
unknown sequences flanking known sequences such as retroviral DNA. (76, 132). 
Therefore. IPCR is used to detect the monoclonality of HTLV-1 infected cells.
RETROVIRAL REPLICATION
A virus is a life form that lacks its own metabolism, and is therefore dependent on
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIG. 1. Retroviral life cycle. The virus particle attaches to the host cell and through the 
catalytic activities o f retroviral enzymes, a new virus is produced.
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6the metabolic apparatus o f a host cell for its replication. The core structure of a retrovirus 
contains its genetic code in two RNA molecules. In addition, each virus particle contains 
enzymes and other proteins that are required for infection of host cells and conversions o f 
them to virus factories. The surface of the virus particle contains glycoprotein molecules 
that mediate attachment o f the virus to a receptor protein (CD4 ) located on the plasma 
membrane o f the infected cell (Fig. 1). Upon entry into the host cell, the subviral complex 
containing the genomic RNA molecules and limited viral proteins is released into the 
cytoplasm (124). Single-stranded RNA chains are converted to double-stranded DNA by 
the enzyme, reverse transcriptase. The double-stranded DNA is then integrated into the 
host genome by another enzyme, integrase. to form the provirus.
The viral proteins take over the control functions of the host cell and can start 
making new viral particles. The reverse transcriptase enzyme of the host cell starts to 
produce multiple copies of messenger RNA encoding new viral materials. Translation of 
the mRNA results in the production of long peptide chains. The long peptide chains or 
polypeptide precursors and viral RNA are then exported to budding particles that form on 
the cell surface. Completion o f the virion occurs by pinching off the budding particle at the 
cell surface. In the last stage o f budding, the polyprotein precursors are proteolvtically 
cleaved at domain boundaries by the viral protease to liberate mature proteins.
MOLECULAR ORGANIZATION OF HTLV-1
As previously stated, HTLV-1 has been associated with a wide spectrum of 
clinical manifestations including cancer, immunological manifestations and neurological 
disorders. Because of its clinical relevance, the genes of the retrovirus have become a 
focal point o f  retroviral research for scientists today. As depicted in Fig. 2. the viral 
genome o f the HTLV-1 pro virus consists o f two long terminal repeats (LTR), the typical 
gag, pro. pol. and env genes, and a novel 3‘ end which encodes the two trans-regulatorv 
proteins, tax and rex (120-121).
The LTR enables the genome to insert itself into the genome o f  a host cell. In the 
proviral DNA. the LTR contains signals which control and affect transcription, splicing, 
and packaging of RNA into virions.
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7The gag  and env genes are known to be essential for the production o f infectious 
progeny virus, in that, they encode proteins that constitute the virus structure. The gag 
gene encodes structural proteins, specifically the core proteins p 19 (matrix protein) and 
p24 (capsid protein). The protease is primarily responsible for processing of the gag gene 







FIG. 2. HTLV-1 genome. Long terminal repeats (LTR) and open reading frames are 
depicted. ) denotes frameshift sites.
includes an RNA-directed DNA polymerase, the reverse transcriptase, an RNaseH region 
which degrades viral RNA in the immediate wake o f its reverse transcription and an 
integrase or endonuclease region which integrates the newly synthesized DNA into the 
host genome.
The env gene encodes the precursor envelope protein. gp61. G p61 is cleaved by 
an unknown cellular enzyme to yield the small transmembrane (gp2l) and large external 
envelope (gp46) glycoprotein. Gp46 interacts with a still unidentified cellular receptor to 
facilitate viral entry (22).
There exists a long ORF between the env gene and the 3*-LTR which is called the 
pX region. Double spliced mRNA enables this region to encode two regulatory genes, 
tax and rex. These regulatory genes are essential in controlling viral RNA and protein 
synthesis (86). Expression products o f these genes yield proteins not present in the virus 
itself. The Tax protein is located in the nucleus and enhances viral transcription by
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8activation o f three 21 base pair enhancer elements located in the U3 region o f the viral 
LTR (155). Tax does not actually bind to this region, rather, it activates different cellular 
transcription factors that in turn bind to this region. IL-2a and its receptor are responsive 
to transactivation by Tax and expression of this receptor in HTLV-1 transformed cells has 
been reported (22). The Tax protein also activates sequences to which the nuclear factor 
kB (NFkB) binds and thereby may induce a set of genes expressed during T-cell 
activation.
The Rex protein is also located in the nucleus and functions in regulating the 
levels of unspliced to spliced viral mRNA. Rex is responsible for exporting full length 
gag/pol mRNA and single spliced env mRNA from the nucleus to the cytoplasm (55.
106). Export of mRNA is achieved by binding o f a phosphorvlated Rex protein to cis- 
acting RNA sequences . called the rex responsive elements in the viral RNA (4. 8. 11,3.
119. 152). The Rex protein is therefore regarded as a positive regulator o f expression of 
structural proteins o f HTLV-1. However, an overexpression o f rex may lead to negative 
regulation. Thus. HTLVs possess a self-regulatorv mechanism to control their replication 
by products of the tax and rex genes (49).
RIBOSOMAL FRAMESHIFTING
All o f the genes in the retroviral mRNA produce proteins essential for the surviv al 
o f  the virion. However, not all virion particles that are produced are infectious. The 
proteins translated from the mRNA in the nucleus are long polypeptide chains or 
polvprotein precursors which are transported to the cell membrane and incorporated in 
the virion. The budding virion is not considered infectious until the protease cleaves the 
polyproteins into their respective structural proteins. The mature virion components are 
generated by proteolytic cleavage o f the primary translational products o f the genome 
sized mRNA. designated the Gag, Gag-Pro. Gag-Pol, and Gag-Pro-Pol polyproteins. The 
synthesis o f Gag-Pro, Gag-Pol, and Gag-Pro-Pol fusion proteins, which all share the 
common gag initiator codon located at the 5'end o f the gag gene, is translationally 
regulated. Two general mechanisms by which the synthesis o f the fusion proteins can be 
achieved are known: readthrough suppression and ribosomal frameshifting.
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9In readthrough suppression, an amino acid is inserted (by a suppessor tRNA) 
where a stop codon is located. Through the actions o f these suppressor tRNAs, some 
ribosomes are able to bypass the designed stop codon during translation o f the mRNA 
and a fusion protein is produced instead of the Gag polyprotein.
In mammalian type C retroviruses, the gag amber terminator (UAG) is suppressed 
by a glutamine-tRNA to translate the pol gene (153). However. Nam. et al. found in 
HTLV-1. that the Gag-Pro fusion protein occurs by ribosomal frameshifting (85). 
Ribosomal frameshifting involves the slippage of a tRNA one nucleotide in a forward or 
reverse direction. As a result, the gag and gag-pol sequences are out o f frame with 
respect to each other. In the HTLV family of retroviruses. Bovine Leukemia Virus 
(BLV). Mouse Mammary Tumor Virus (MMTV) and type D retroviruses. the,gt/gand 
pol genes are separated by a pro ORF that overlaps both gag and pol (48. 8 1. 84. 98. 102. 
108 117 127. The protease gene may be located at either the 3'end o f gag  or the 5' end of 
pol i.e. Human Immunodeficiency Virus 1 (HIV-1) and Rous Sarcoma Virus (RSV)
(115. Thus. HTLV-1 utilizes a slight variant of the frameshift mechanism to form their Pol 
proteins. Two successive frameshifts must occur: (1) moving from the gag reading frame 
into a short intermediate gene encoding the protease, and (2) moving from that reading 
frame into the pol frame (Fig. 2). These frameshifts occur by a slippage o f asparagine 
tRNA Oin the - I  direction (83-84).
PROTEOLYTIC PROCESSING
After the HTLV-1 tusion proteins are translated, they are proteolytically processed 
by the retroviral protease to produce the Gag. Pro and Pol proteins. The viral protease is 
encoded in a separate reading frame overlapping the gag/pol coding sequences (23. 32) 
(Fig. 2). Thus, the protease must, itself, be excised from a precursor protein. The 
protease may autoprocess from within its precursor protein by cis catalysis.
Alternatively, the protease may be cleaved by trans catalysis through the actions o f a 
neighboring Gag-Pol precursor (23).
Through site-directed mutagenesis studies, Nam et al. (1988) determined that the 
catalytic center o f the HTLV-1 protease, consisting o f one o f the two conserved regions
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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common to retroviral proteases, was identical to that o f an aspartyl protease (85). Other 
reports confirm that mutations in Asp123 abolish protease activity (58. 82). Retroviral 
aspartic proteases have a optimal pH range of 4-6 while eukaryotic aspartic proteases 
have an optimal activity range o f pH = 2-4. The difference in optimal activity range has 
been attributed to the lack o f hydrogen bonding between Asp and Thr or Ser in eukaryotic 
proteases. In retroviral proteases, the corresponding Thr or Ser is replaced by Ala. No 
corresponding hydrogen bonding can occur: thus, the active Asp becomes less acidic, and 
the pH optimum increases (33).
The mechanism by which the HTLV-1 protease cleaves its substrate is modeled 
after that o f the HIV-1 protease since they are both aspartic proteases (46-47. 54) (Fig. 3). 
The aspartic residues in the active site o f each monomer share a proton. The lytic water 
molecule forms hydrogen bonds to the charged carboxylate. The Cp-C, bond of A sp125 
rotates to allow its proton to hydrogen bond to the carbonyl oxygen of the substrate. The 
Asp25 becomes more basic than Asp123 due to the loss of the shared proton. The proton 
from the lytic water can be abstracted to the carbonyl oxygen, forming a protonated 
amide species. EA'H. The carbonyl carbon of EA'H becomes an electrophilic substrate 
for the water molecule. The amide hydrate intermediate. EXH. is then formed. Two 
proton transfers lead to the tetrahedral intermediate EX'H. Finally the peptide bond is 
broken and the fragments are created. The enzyme is then released in free form and may 
process more substrate.
HTLV-1 REVERSE TRANSCRIPTASE
While a considerable amount o f information is known about the structure o f the 
protease and gag proteins, not much is known about the structure and proteolytic 
processing o f the reverse transcriptase o f HTLV-1 RT. Therefore, to further our 
knowledge of molecular events during retroviral DNA synthesis, it is essential to 
understand the architecture and functional organization of the reverse transcriptase 
molecule. Information about HTLV-1 RT. would allow for better understanding o f the 
biology o f these viruses.






FIG. 3. Proteolytic mechanism for the hydrolysis o f  the Pro-Pol protein. The aspartic 
residues o f  the tree enzyme (EH), share a proton. After attack o f the substrate (EAH), a 
protonated amide species is formed (EA'H). The carbonyl carbon o f EA'H is attacked by 
water to form the amide hydrate intermediate. EXH. After two proton transfers, a 
tetrahedral intermediate is formed (EX’H). Finally the peptide bond is broken and the 
products are free to dissociate. The enzyme can then trap another water molecule.
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The reverse transcriptase (deoxynucleoside triphosphate, DNA deoxynucleotidyl 
transferase, RNA-directed E.C. 2.7.7.49) o f all retroviruses is encoded by the pol gene and 
synthesized by the translation of a full length viral mRNA, identical in structure to the 
genomic RNA packaged into virions. It is never expressed as a separate protein, but rather 
translated as part o f a large Gag-Pro-Pol protein (polyprotein precursor) (65). The reverse 
transcriptase exhibits three enzymatic activities: RNA-dependent DNA polymerase. 
Ribonuclease H (RNaseH) and DNA-dependent DNA polymerase (54). All o f these 
enzymatic activities are essential for transcribing the single-stranded genomic RNA found 
in the virions into the double-stranded linear DNA that is the precursor to the integrated 
provirus.
The process o f reverse transcription is depicted in Fig. 4. As in the case o f all 
DNA polymerases. RT needs a primer carrying a free 3'-OF! group to initiate DNA 
synthesis. Retroviruses use host-encoded tRNAs as primers (64. 67. 72. 75). The tRNA 
anneals to the primer-binding site (PBS) located near the 5' end o f the viral plus-strand 
RNA. The RT recognizes the tRNA/RNA complex and initiates reverse transcription of 
the minus-strand DNA by extending the 3' end of the primer. The recessed template 
strand guides DNA synthesis (6. 50). In copying the U5 and R regions of the genome, 
the RT forms a strong stop cDNA. Coupled with the synthesis o f DNA is the degradation 
o f the RNA strand o f  the newly formed RNADNA hybrid by the RNaseH (25. 34. 114).
The strong stop DNA is transferred to the 3'end o f genomic RNA in order to 
continue synthesis o f the minus-strand DNA. This first strand transfer is facilitated b\ a 
complementary R region at the 3'end o f  the viral RNA. The two complementary R 
sequences allow hybridization o f minus-strand DNA with plus-strand RNA, permitting 
DNA synthesis to resume. As previously, the RNaseH activity o f the RT degrades the 
RNA template. Synthesis of minus-strand DNA also entails the creation o f purine rich 
fragments that function as RNA primers for plus-strand DNA synthesis (13-14. 45. 56, 
146). Thus, the minus strand U3-R-U5 still attached to the tRNA primer is copied to 
form the plus-strong-stop DNA. As plus-strand DNA synthesis proceeds to the PBS, the 
original primer tRNA is degraded by the RNaseH activity.
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FIG. 4. Retroviral reverse transcription. The reverse transcriptase produces a double­
stranded DNA from a single-stranded RNA through a sequence o f steps involving two 
stand transfer events. The resulting linearized DNA is called the proviral DNA and is 
inserted into the host to form the provirus.
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Once the primer tRNA is released, the second strand transfer occurs. The PBS on 
the plus-strong-stop DNA anneals to the complementary PBS on the 3' elongated minus 
strand and ligation o f the circular intermediate produces a linear duplex with LTRs (54). 
The LTRs are duplicate R. U5. and U3 sequences. Thus, the proviral DNA differs in 
length compared to the original RNA genome whose LTR contain the R region and either 
the U5 or U3 region, respectively. The proviral DNA is then integrated into the host to 
form the provirus.
There are common biochemical properties of RT from different viruses, i.e. primer- 
templates and divalent cations. But. they also differ in molecular weight, in subunit 
composition, function, and in their sensitivities to polymerase inhibitors. For example. 
Murine Leukemia Virus RT is a single polypeptide chain that carries both reverse 
transcriptase activity and RNaseH activity, while some retroviral reverse transcriptases 
may be divided into two domains each exhibiting only one enzymatic activity. Avian 
Myoblastosis Virus RT consists o f two subunits, alpha and beta. The larger subunit 
carries the integrase function as well as the RNaseH and polymerase activities: the 
smaller subunit carries polymerase and RNaseH activities (43, 125)
PREVIOUS RESEARCH
To date, not much is known about the reverse transcriptase of HTLV-1.
Retroviral polymerases from different taxonomic classes show a preference for certain 
synthetic template-primer combinations. Transcription also requires a divalent cation: 
Mg2' or Mn: \  The majority o f retroviruses preferentially use Mg2' (65). In the first 
reported information about HTLV-l RT. Rho et al.( 101) characterized the enzyme from 
the virion. They found that this RT has an apparent MW o f 95.000. that Mg 2' is the 
preferred divalent cation, and that polv(rC)«oligo(dG) is the preferred primer-template in 
vitro. However, this group could not obtain much protein from their isolation method from 
human cell infected lines. Further characterization o f the enzyme was not performed. 
Subsequently. Hoffman et al. found that HTLV-I RT isolated from infected MT-2 cells 
preferred Mn2* with both a po!y(rA)«oligo(dT) and poIy(rCm)« oligo(dG) primer 
template, but Mg2* for a poly(rC)«oligo(dG) template primer (43). Most recently. Owen
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et al. expressed a recombinant HTLV-1 protein with reverse transcriptase activity. This 
protein has an approximate MW of 60,000-65.000, and prefers a Mg2' divalent cation on 
a poly(rC)«oligo(dG) template (91).
The exact sites of protease cleavage have been identified for a number of viral 
polyproteins by comparing the amino acid sequences of the precursors, deduced from the 
proviral DNA sequence. The N- and C-terminal amino acid sequences of mature viral 
proteins were determined by direct protein sequencing techniques. However, the actual 
identity of the authentic N-terminus from virion-produced HTLV-1 RT has not been 
identified from mature, processed protein.
Two very recent reports have been published on the expression o f the RT of 
HTLV-I. In the first. Owen et al. expressed an enzymatically active HTLV-1 RT in 
bacteria. They began their construct such that translation was initiated at Pro” , which is 
located within the proposed pro-pol frameshift site (91). This group made no effort to 
determine the correct N-terminal sequence (proteolytic processing). In the second report. 
Trentin et al. hypothesized that the N-terminus o f the RT should immediately follow the 
known C-terminus o f the protease. By using sequence alignments with other retroviral 
sequences, they demonstrated that there was no known function for the sequence encoded 
between the C-terminus o f the protease and Pro ”. Based on the similarity o f the 
sequence of other RTs. the protein coding sequence should begin at Pro ”. The protein 
resulting from their construct also had RT activity (131). However, they used an in vitro 
transcription/translation system which could have an impact on the overall folding and 
potential subunit structure. In addition, Trentin et al. assumed that the HTLV-1 RT 
sequence is similar to that of the RT of avian sarcoma virus (ASV). Based on this, they 
deduced an oligomeric structure of the RT and claimed to have obtained an exclusive 
enzymatically active RT form, the a ,/p  tetramer. This is a molecular arrangement never 
encountered before in retroviral RTs (16. 41. 125). Taken together, there are 
discrepancies between the two published reports on recombinant HTLV-1 RT. 
Furthermore, Perach et al. (92) found that the amino acid sequence requirements and 
molecular arrangements o f the recombinant BLV RT are substantially different from 
those o f both HTLV-l RT studies. These unique differences among relatively close RTs
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should be helpful to future studies designed to study structure-function relationships of 
these RTs.
HTLV-1 viruses show very limited sequence variation in comparison to a much 
greater variation seen among different isolates of each lentivirus in the HIV/SI V family (28.
30. 57. 71. 77). Ratner et al. reports a l.2%-3.3% nucleotide sequence difference among 
HTLV-1 isolates (100). The identification of possible regions of functional importance can 
be unequivocally determined by comparative sequence analysis because o f the genomic 
stability o f HTLV-1 and minimal strain variation between isolates. As each of the 
functional aspects becomes better understood, targets for antiviral intervention against 
HTLV-1 associated diseases will emerge.
DEVELOPMENT OF THE RESEARCH METHODOLOGY
In light o f the facts presented, the ultimate goal o f this project is to characterize the 
reverse transcriptase enzyme of HTLV-1. Successful expression of this replication 
enzyme would allow for a detailed biochemical characterization as well as a comparison 
of structure-function relationships with reverse transcriptases from HIV and other 
retroviruses. The expression system for the HTLV-1 RT was developed in 1995 by my 
advisor. Dr. Laura Moen. The plasmid, pRCH (generously provided by Dr. Lee Ratner of 
Washington University), which contained the cDNA from a replication competent isolate 
of HTLV-1. was used to create the desired protein expression system. The intact HTLV-I 
pol gene was cloned using a pET vector for expression. The desired sequence was 
amplified using PCR. To mimic the second frameshift in the pol ORF. an extra C was 
inserted at the second frameshift site when the primers were made. Since the expression 
vector used to insert our clone (pET 24) contained the Bam and EcoRl restriction sties, our 
clone was made such that the clone had a Bam site at its N-terminus (Pro158). After the 
expression vector is cut open with Bam and EcoRl restriction enzymes, the clone is ligated 
in the opened vector. This coding sequence was cloned in frame with the 10 amino acid T7 
tag sequence in pET24b to facilitate expression and detection on a Western.
Originally, two clones were created because the structure o f the RT and the cleavage 
sites in pol were unknown. The pol ORF of HIV-I also encodes for reverse transcriptase.
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A + D C + B lo r C  + B2
2nd PCR |  
shorter gene to RNase H
i  ■-
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FIG. 5. Strategy for the amplification o f the intact HTLV-l RT coding sequence. (A) 
Expression system for reverse transcriptase with RNaseH; Mr = 65,000. (B) Expression 
system for reverse transcriptase with integrase: Mr = 99,000.
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RNaseH and integrase (endonuclease) domains. This Pol polypeptide is further processed 
to produce a mature reverse transcriptase and a separate mature endonuclease protein (23). 
The HTLV-I RT protein may act in a similar fashion. On the other hand, the HTLV-I RT 
protein may have similar functions to other reverse transcriptases such as Rous Sarcoma 
Virus RT which possesses both a reverse transcriptase and endonuclease domain (23). 
Given this background information, the clones shown in Fig. 5 were produced: (1) The 
short clone was constructed with a stop codon at amino acid 591 which terminated the 
coding sequence at the end of the RNaseH domain. (2) The large clone included the 
integrase domain and terminated at the native pol stop codon.
Since the sites o f protease cleavage in the pol region have not been identified 
other than those required for the production of mature protease, the clones were created 
with a putative N-terminus. The actual identity of the authentic N-terminus from virion- 
produced HTLV-1 RT has not been identified and confirmed. Dr. Laura Moen and her 
post-doctoral associate, Imogene Richardson, carried out a sequence alignment with 
several reverse transcriptases which included that from Bovine Leukemia Virus, the 
closest characterized relative to HTLV-1. A portion of that alignment, shown in Fig. 6. 
suggests that the N-terminus of HTLV-1 RT is likely to start where the viral protease C- 
terminus ends. Therefore, both of the clones were constructed to contain this sequence at 
the N-terminal region.
HIV-1 P I - S
HTLV-1 P 1 Q A
HTLV -2 P 1 A T
BLV V L D A
I E TV P V K 
- A V -  L 
- N T - 1  
- -  S H - I
K . P G M D G P K . V K
G L E H L P R P P E  1 S Q  F P L N P E R
G L E H L P P P P Q V  C O F  P L N P E R
G L E H L P V P P E V P Q  F P L N L E
W P L T E E
FIG. 6. Sequence to determine the N-terminus of HTLV-l RT. The amino acid 
sequences at the N-terminal regions o f  HIV-1 and BLV RTs are aligned with the N- 
terminal regions for HTLV-1 and HTLV-2. The last boxed region contains the sequences 
surrounding the frameshift in the pol reading frame (between L and N o f HTLV-1 and 
HTLV-2).
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RESEARCH OBJECTIVES
As previously stated, Owen et al. reported that a smaller recombinant protein from 
an MT-2 HTLV-1 cDNA exhibits RT activity (91). The coding sequence o f this protein 
begins after the ribosomal frameshift and ends at the end o f the RNaseH domain. Efforts 
to produce the short clone which would be analogous to that reported by Owen et al. did 
not succeed; the smaller protein was rapidly degraded as it was synthesized. The 
instability o f this protein that was observed may be due to as yet undetermined protein 
folding differences between the two proteins and perhaps by the different expression 
systems employed. The results of expression of the longer clone which included the 
integrase domain, however, showed significantly higher levels of expression on Western 
blots. It is with this longer clone that a purification scheme was developed. Further 
investigation was necessary to clarify the reasons for folding differences and to 
unequivocally identify the mature form of the authentic HTLV-1 RT. The specific aims 
of this research are to:
I. Purify' a recombinant HTLV-I RT 
With the availability of primary sequences for RNA-dependent DNA polymerases, it has 
become possible to compare and delineate some of the highly conserved regions found in 
polymerases from diverse origins. Sequence alignments among these polymerases have 
revealed four conserved motifs (94). Genetic studies of these conserved regions have 
demonstrated a critical role for these residues in the catalytic function of these 
polymerases (9. 31. 62. 97. 109). For example, the invariant DD motif in motif 3 o f these 
polymerases is thought to be at the polymerase active site. For related polymerases, 
published procedures can be used as a starting point and modifications made later to 
improve the specific activity, purity, and recovery of the enzyme. Since the location o f 
the active site o f the HTLV-1 RT is not known and thus, the amino acids involved in 
catalysis, other retroviral reverse transcriptase purification schemes were used as a basis. 
Consequently, several different ligands were analyzed.
Several sensitive methods exist for protein characterization. These 
chromatographic methods include ion exchange. DNA affinity, metal chelate affinity, 
hydrophobic interaction, precipitation, ammonium sulfate, polyethyleneimine and high
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performance liquid chromatography (HPLC). All of these methods were used to 
empirically determine the optimal conditions for adsorption o f the RT. Analysis of purity 
of the final product was assessed using SDS-PAGE analysis, gradient gels, gel filtration. 
Western Blotting, and measurement o f reverse transcriptase activity. Further 
characterization involved template specificity and stability studies.
2. Confirm the proteolytic processing site o f  the N-terminus o f  HTL V-l RT  
Results from the stability studies were in agreement with others in that the activity of the 
enzyme is consistently low. An earlier report by Hizi. et al. demonstrated that the first 20 
amino terminal acids o f HIV-1 RT are required for an active enzyme (42). The low 
activity observed in this study and/or others may be due to an incorrect coding sequence 
for the HTLV-I RT. Moreover, the N-terminal proteolytic cleavage site of HTLV-l RT 
has not been determined. Therefore, to confirm the HTLV-1 RT purified in this project 
contains the authentic N-terminus. clones coding for the expression o f a protein fragment 
spanning the pro-pol junction were constructed. The clone was purified using methods 
described in objective 1 and cleaved using recombinant HTLV-1 protease.
The peptide fragments were analyzed by LC-MS and MS/MS at the 
Biomoiecular Research Facility at the University o f Virginia by Dr. Nicholas Sherman.
In recent years, mass spectrometric methods have emerged as powerful tools for protein 
characterization (124). Protein amino acid sequences can be determined by tandem mass 
spectrometry using a triple-quadrupole mass spectrometer. In this process, protonated 
peptide ions are selected with the first mass spectrometer and are transmitted to a 
collision cell. Low energy collision with neutral inert gases results in fragment ions that 
are then detected in a second mass spectrometer. The fragmentation patterns o f peptides 
obtained are indicative o f their amino acid sequences and thereby allow for the 
determination of peptide sequences as well as determination o f any posttranslational 
modifications occurring within the protein. Analysis o f the Pro-Pol protein fragments by 
LC-MS and MS/MS was used to determine the location o f the cleavage site which is 
presumably used to generate mature reverse transcriptase from Gag-Pro-Pol polyproteins 
expressed in vivo in HTLV-1. Since the sequence o f the Pro-Pol protein is already
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known, confirmation of the peptide fragments can be rapidly performed by mass 
measurement.
PROJECT SUMMARY
The retroviral replicative cycle has been intensively studied in order to identify 
possible targets for designing inhibitors, which may become powerful therapeutic agents. 
While HTLV-1 is not as prevalent as other retroviruses i.e. HIV. coinfection with HIV may 
have a serious impact. In order to deal with the consequences of a widespread infection and 
disease before an epidemic occurs, we can study the replicative mechanisms of HTLV.
The reverse transcriptase plays a crucial role in the early stages of viral replication. 
To understand the architecture and functional organization o f the reverse transcriptase 
molecule, a recombinant enzyme expressed in E.culi will be purified. By using a 
recombinant source o f HTLV-l RT. some of the biochemical properties o f HTLV-l RT can 
be determined. Confirmation of the protein as authentic will provide a basis for further 
studies on the structural aspects of protein nucleic acid interaction.




To optimize the growth of the two different types o f E. coli strains, nutrient rich 
media was prepared. Luria Broth (LB: Difco. Detroit. MI) was prepared by dissolving 25 
g o f  LB powder in 1 L MiiliQ water to a final concentration o f 10 g bacto-tryptone, 5 g 
bacto-yeast extract and 10 g NaCl per liter o f LB. The solution was autoelaved 
(Sterilmatic. Market Forge Co.. Everitt. MA) at 240°C for 20 minutes.
1.4 g of agar (Fisher. Indianapolis. IN )/100 mL LB was autoelaved to create solid 
media for pouring plates. After cooling to 50°C. the solution was poured into sterile petri 
dishes (Fisher)) and allowed to polymerize at room temperature. If antibiotics were 
required in the media to enhance the growth o f plasmid DNA and/or E. coli cultures, they 
were added to the media upon cooling to 50°C.
PREPARATION OF COMPETENT E. coli
The preparation o f BL2l(DE3)pLysS (Novagen. Madison, WI) and W3110(DE3) 
competent E. coli was performed using the CaCL method outlined in Current Protocols in 
Molecular Biology (16). The BL21(DE3)pLysS host strain carries a plasmid with the T7 
Ivsozyme gene which confers resistance to chloramphenicol. In which case. LB media 
was supplemented with chloramphenicol to a final concentration o f 34|ug/mL in all steps 
o f this procedure. Unless otherwise stated, any protocol described hereafter in which the 
BL21(DE3)pLysS host E.coli strain is grown, utilizes LB supplemented with 34 fig/mL 
chloramphenicol as its growth media. The 34 mg/mL chloramphenicol stock solution 
was made by dissolving 34 mg of chloramphenicol (Fisher) in I mL 100% ethyl alcohol 
(AAPER Alcohol and Chemical Co., Shelbyville, K.Y).
An LB plate was streaked with the E. coli strain o f choice using a sterile 
inoculation loop. The plate was incubated in a 37°C incubator (Fisher) for approximately 
14-16 hours. The following day, a single colony was used to inoculate 3 mL o f LB
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media. The single colony was grown overnight at 37°C while shaking at 250 rpm (Orbit 
Environ Shaker. Lab-Line Instruments. Inc.). On the third day. a 1 mL aliquot o f the 
overnight culture was inoculated into 100 mL sterile LB media in a 500 mL flask. The 
culture was grown at 37°C. while shaking at 250 rpm. to an O.D.*,,,, = 0.375. The culture 
was divided into 50 mL aliquots by pouring the culture into two pre-chilled. sterile, 
polypropylene centrifuge tubes. After leaving the tubes on ice for 10 minutes, the 
suspension was centrifuged for 7 minutes at 3000 rpm (Beckman GPR. Fullerton. CA).
At all centrifugation steps in this protocol, the tubes were allowed to decelerate without 
braking. The supernatant was discarded and each pellet was resuspended in 10 mL ice- 
cold, filter sterilized CaCL (60 mM CaCL. 15% glycerol. 10 mM PIPES. pH 7). The 
suspension was centrifuged for 5 minutes at 2500 rpm. The supernatant was again 
discarded and each of the pellets resuspended in 10 mL ice-cold CaCL. The suspended 
bacteria were kept on ice for 30 minutes and were centrifuged again for 5 minutes at 2500 
rpm. In the last step, the supernatant was discarded and each of the pellets was 
resuspended in 2 mL ice-cold CaCL. These competent bacteria were stored in 16-250 p.L 
aliquots in 1.5 mL sterile, polypropylene tubes (Fisher) at -70°C.
EXPRESSION SYSTEMS
A plasmid pRCH (generously donated by Dr. Lee Ratner of Washington 
University) containing the entire genome from an HTLV-l strain was used to amplify the 
entire coding region for the polymerase and the protease. The cDNAs were prepared by 
Dr. Laura Moen and Barbara Conyers using a Perfect Prepi£> (5 Prime—> 3 Prime.
Boulder, CO) DNA preparation kit. All three expression systems were developed using 
pET vectors (Novagen). These cloning vectors contain specific antibiotic resistant genes 
to allow for growth selection on media plates. Both pET24 and pET29 carry the 
kanamvcin resistant gene. pET19 carries the ampicillin resistant gene.
The RT coding sequence was cloned in-frame with the 10-amino acid T7 tag 
sequence in pET24b which facilitated the detection o f the expression product by Western 
blot. The protease coding sequence was cloned in-frame with an N-terminal 
polyhistidine tag (His-tag) in pET19, which facilitates purification with an immobilized
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nickel affinity column. A Pro-Pol protein clone, which spans a region where the protease 
is known to terminate and continues past the pro-pol frameshift. was cloned in-frame 
with the N-terminal 16 amino acid S-tag in pET29 which facilitates detection o f the 
expression product by Western blot. The coding sequence also contained a C-terminal 
His-tag.
Before transformation in E. coli. the plasmid DNAs were digested with the 
appropriate restriction enzymes and analyzed by agarose gel electrophoresis to confirm 
that the correct plasmids were obtained. Because the DNA is cut at specific sites, a 
distinct pattern o f bands for each cDNA is apparent with ethidium bromide staining. The 
plasmid DNAs. pET24ab3#12 (RT), IK 19 (protease), and peptide (Pro-Pol protein) were 
stored as glycerol stocks in either XL-Blue or AG1 cells.
ISOLATION OF PLASMID DNA
A BIGGER prepoD Plasmid DNA Preparation Kit (5 Prime -> 3 Prime. Inc.) was 
used to prepare plasmid DNAs for the HTLV-1 RT. the HTLV-1 protease and the Pro-Pol 
protein expression constructs. Unless otherwise stated, all steps in the procedure were 
performed at room temperature. The DNA stock was streaked on an LB/agar plate 
supplemented with appropriate antibiotic and grown for 14-16 hours in a 37°C incubator. 
25 mg/mL stock kanamvcin was made by dissolving 25 mg of kanamycin (Sigma. St. 
Louis. MO) in I mL MilliQ water. If supplemented with kanamycin, the 25 mg/mL stock 
was added to final concentration of 50 pg/mL in media. To supplement media requiring 
ampicillin, the appropriate number o f 2.5 mg ampicillin tablets (Stratagene. La Jolla, CA) 
was dissolved directly in media to give a final concentration o f 100 pg/mL ampicillin.
The following day, the plate was stored at 4°C until late afternoon, at which time, 
a single colony was inoculated in 500 mL LB with the appropriate antibiotic and 
incubated overnight at 37°C with shaking at 250 rpm. The bacteria was pelleted in 2-250 
mL centrifuge bottles by centrifugation (Beckman Model J 2-21) at 10,000 x g for 3 
minutes. The supernatant was discarded and the plasmid DNA was isolated from the 
pellet by following the manufacturer’s instructions. In brief, the pellet was treated with a 
buffered RNase A solution, lysed with alkaline lysis solution, and neutralized with
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potassium acetate solution. Unless otherwise stated, all solutions were provided in the 
preparatory kit. The plasmid DNA in the neutralized bacterial lysate was then bound to a 
DNA binding matrix suspension. The resulting DNA binding matrix/plasmid DNA 
solution was washed with several aliquots o f buffered salt solution followed by elution o f 
the purified plasmid DNA with heated TE solution. pH 8.0. The eluted purified plasmid 
DNA was then precipitated by the addition of 5 M NaCl and 95% ethanol. The solution 
was mixed and the plasmid DNA was pelleted by centrifugation at 16.000 x g for 5 
minutes. After carefully removing the supernatant, the plasmid DNA pellet was washed 
twice with 70% ethanol and air dried overnight to remove the ethanol. The next day. the 
pellet was resuspended in 100 pi sterile water to rinse the side of the tube. The purified 
plasmid DNA was transferred to a 0.5 mL sterile, siliconized, eppendorf tube (Fisher) and 
stored at -20°C.
QUANTITATION OF DNA
An aliquot o f the DNA sample was diluted either 1:50 or 1:100 with sterile water. 
The amount o f DNA in the samples was determined spectrophotometrically using the 
Cary UV/VIS Spectrophotometer (Varian Model 3-Bio. Palo Alto. CA). The absorbance 
of the dilute sample was read at 260 nm and 280 nm. The reading at 260 nm allows for 
the calculation o f the concentration o f nucleic acid in the sample. An O.D. = 1 
corresponds to approximately 50 pg/mL for double-stranded DNA. Thus, the following 
equation was developed to calculate the concentration o f nucleic acid in the sample:
A:fi0 x dilution factor x 50 pg/mL = X pg/mL DNA
The ratio between the readings at 260 nm to 280 nm provides an estimate for the purity o f 
the nucleic acid. If this ratio was near 1.8. the original DNA sample was stored at -20°C 
and used for the transformation of plasmid DNA in E. coli.
TRANSFORMATION OF COMPETENT E. coli WITH PLASMID DNA
Because the competent E. coli were stored in CaCL. they were exposed to 
calcium ions which allow the cells to take up DNA. The bacterial cell membrane is 
permeable to chloride ions, but is non-permeable to calcium ions. As the chloride ions
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enter the cell, water molecules accompany the charged particle. This influx o f water 
causes the cells to swell and is necessary for the uptake o f DNA. The exact 
mechanism o f  this uptake is unknown. It is known, however, that the calcium chloride 
treatment must be followed by heat.
A 250 pL aliquot of competent E. coli was allowed to thaw on ice. 100 p.L of E. 
coli was transferred to a 14 mL sterile, round bottom, polypropylene tube (Fisher) which 
was also kept on ice. The bacteria were incubated with 1.7 pi o f a 1:10 dilution o f P- 
mercaptoethanol (Fisher) for 10 minutes with gentle swirling every two minutes. 
Approximately 1 pg of DNA (~ 1-2 pL) was added to the cells and the solution was 
allowed to incubate on ice for 30 minutes.
When E. coli are subjected to 42°C heat, heat shock genes are expressed which 
aid the bacteria in surviving at such temperatures. The heat shock step is necessary for 
the uptake o f DNA. At temperatures > 42°C. the bacteria's ability to uptake DNA 
becomes reduced, and at extreme temperatures the bacteria will die. Therefore, in the 
next step the tube was placed in a 42°C water bath for 45 seconds. The tube was then 
quickly placed in ice for 2 minutes. 900 pL of sterile SOC media (0.5% yeast extract. 
2% tryptone. 10 mM NaCl. 2.5 mM K.C1. 10 mM MgCL, 10 mM MgSO^and 20 mM 
glucose) was added to the tube and the tube was incubated for I hour at 37°C with 
shaking at 250 rpm. All of the bacteria were pelleted by centrifugation at 1000 rpm for 
10 minutes. The supernatant was gently discarded and the remaining slurry o f pelleted E. 
coli DNA was plated on an LB/antibiotic plate using a spreader to evenly distribute the 
bacteria. The spreader was initially sterilized by dipping the spreader in ethanol, passing 
the spreader through a gas flame to ignite the ethanol, and allowing the flame to bum out. 
The spreader was cooled by touching the surface o f the LB plate. The plate was 
incubated overnight in a 37°C incubator.
The next morning the plate containing several isolated colonies was stored at 4°C 
until ready to be cultured. Ideally, the plates should not be stored for more than one 
week.
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PREPARATION OF BACTERIAL PELLETS
Reverse Transcriptase 
Ten flasks containing 500 mL Luria Broth, 50 pg/mL kanamycin were inoculated with a 
single colony each of W3110(DE3) containing the pET24ab3#12 expression plasmid. 
The flasks were incubated with shaking at 37°C until the culture reached an O.D.gQO ° f
0.6-0.9. at which point 800 mM isopropyl-P-D-thiogalactoside (IPTG; Promega. 
Madison. WI) was added to a final concentration o f 1 mM. 2 hours after the addition of 
IPTG. cultures were pelleted by centrifugation at 10.000 RPM for 20 minutes at 4°C.
The cultures were harvested in 250 mL bottles. The supernatant was discarded with care 
so as not to disturb the bacterial pellet. Two 250 mL pellets were scraped from the bottle 
and combined into one 500 mL pellet on a tared piece o f aluminum foil so that the 
pellet's wet weight could be measured. Finally, the pellet was wrapped in the aluminum 
foil. labeled with its wet weight and stored at -70°C. All 10-500 mL pellets were 
harvested in the same manner.
Protease
A flask containing 100 mL Luria Broth. 100 pg/mL ampicillin and 34 |ig/mL 
chloramphenicol was inoculated with a single colony of BL2lpLysS(DE3) containing 
the protease expression plasmid. The flask was incubated with shaking at 37°C until the 
culture reached an O.D.600 of 0.6-0.9. at which point 800 mM IPTG was added to a final 
concentration o f I mM. 2 hours after the addition of IPTG, cultures were pelleted by 
centrifugation at 10.000 RPM for 20 minutes at 4°C. The supernatant was discarded with 
care so as not to disturb the bacterial pellet. The 100 mL pellet was scraped from the 
bottle and transferred to a tared 2.0 mL round bottom, self-standing cryovial (Fisher).
The cryovial was labeled with the pellet wet weight, frozen in liquid N2 and stored at - 
70°C.
Pro-Pol protein
Two flasks containing 500 mL Luria Broth, 50 pg/mL kanamycin and 34 pg/mL 
chloramphenicol were inoculated with a single colony each o f BL21pLysS(DE3) 
containing the Pro-Pol expression plasmid. The flasks were incubated with shaking at
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37°C until the culture reached an O.D.^OO of 10-1.2, at which point 800 mM IPTG was 
added to a final concentration o f I mM. 45 minutes after the addition of IPTG. cultures 
were pelleted by centrifugation at 10.000 RPM for 20 minutes at 4°C. The cultures were 
harvested in 250 mL bottles. The supernatant was discarded with care so as not to disturb 
the bacterial cell pellet. Two 250 mL pellets were scraped from the bottle and combined 
into one 500 mL pellet on a tared piece of aluminum foil so that the pellet’s wet weight 
could be measured. Finally, the pellet was wrapped in the aluminum foil, labeled with its 
wet weight, frozen in liquid N: and stored at -70°C. Both 500 mL pellets were harvested 
in the same manner.
PREPARATION OF CHROMATOGRAPHIC RESINS
Phosphocellulose (P-l 1)
To determine the amount of phosphocellulose cation exchanger (Whatman. Maidstone, 
England) resin to pre-cycle, the approximate bed volume was approximated using the 
standard formula for the volume o f a cylinder:
volume = 7t x r  x h r = radius o f the column
h = height of the column
With a column height = 20 cm and column i.d. = 5 cm. the bed volume would be 392 mL. 
The amount o f dry phophocelluiose will swell to double its volume in MilliQ water. 
Therefore, approximately 200 mL o f dry phosphocellulose resin was placed in a 1 L 
graduated beaker and allowed to swell in 300 mL MilliQ water. After the resin had 
settled, the water was carefully decanted. Two-500 mL washes of 1 N NaOH (Fisher) 
were added to the beaker to start the basic pre-cycling. The resin was allowed to settle 
for 5 minutes between washes. The 1 N NaOH was decanted into a waste beaker. The 
resin was washed with 250 mL aliquots of MilliQ water until a pH < 10 was reached. 
Each time, the resin was allowed to settle for 5 minutes before decanting.
Acid pre-treatment followed by adding two 500 mL volumes o f IN HC1 (Fisher) 
to the resin. The resin was allowed to settle for 5 minutes and the acid was decanted.
The resin was washed with 250 ml aliquots of MilliQ water until a pH > 4 was reached.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
29
The resin was washed once more with 500 mL MilliQ water. The final phophocellulose 
slurry was incubated with I L o f 10X Reverse Transcriptase Buffer (RTB: 500 mM K.CI 
500 mM Tris, pH 7.5. 25 mM EDTA, 1% Triton X-100) and stored in a 1 L bottle at 4°C. 
All reagents in the buffer were purchased from Fisher.
After the phosphocellulose slurry had equilibrated in the 10X RTB for at least two 
days, the buffer was decanted, and the bottle o f phosphocellulose slurry was warmed in a 
30°C water bath for 1 hour. Approximately 500 mL of RTB-50 (IX  RTB; 50 mM K.C1. 
50 mM Tris. pH 7.5. 2.5 mM EDTA. 0.1% Triton X-100) was added to the media slurry. 
Meanwhile. 500 mL RTB-50 was poured into an empty column (BioRad. Hercules. CA) 
to wash the column and to determine if the stopcock was functioning properly. The 
column outlet was opened to allow 5% of the buffer to flow out and to remove air from 
the space beneath the column bed support and the outlet tubing.
After 5% o f the buffer had passed through the column, the column was packed 
with the phosphocellulose slurry. The 1 L bottle o f slurry was swirled several times and 
the slurry was added to the column in one single operation. The resin was allowed to 
settle by gravity with the column outlet closed. After the bed was formed, the outlet was 
opened and the excess liquid on the top o f the column was allowed to enter the bed. until 
approximately 1 cm remained above the bed surface. The column was equilibrated in 
RTB-50 by running the buffer through the column until the pH of the eluate was 7.0.
Sepharo.se CL-6B
The gel filtration media, sepharose CL-6B (Pharmacia Biotech. Uppsala, Sweden), was 
resuspended by shaking the bottle. 700 mL o f the resuspended gel was transferred to a 1 
L flask. The gel was allowed to settle, the excess liquid was decanted and the gel was 
resuspended in 500 mL RTB-50. The excess buffer was decanted after settling, and 300 
mL o f RTB-50 was added to the gel to make a slurry The slurry was then de-gassed by 
bubbling in N-, for I hour.
Meanwhile. I L o f RTB-50 was poured into the outlet tubing o f an empty column 
(XK 50/60, Pharmacia), until it passed through the bed support net. The column outlet 
was closed when the dead space under the net was properly filled. The entire slurry was 
poured into the column in a single operation using a reservoir. The outlet valve was
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opened and the packing o f the column was initiated by gravity flow. When all the gel had 
sedimented to the bottom, the reservoir was removed and the adapter was inserted. The 
flow adapter was adjusted to the surface o f the gel bed when the gel was thoroughly 
packed into the column. The column was equilibrated with 2 L of RTB-50 by running 
the buffer through the column overnight in a 4°C cold box. The column remained at 4°C 
for the entire standardization and purification procedures.
Gel filtration molecular weight markers (Sigma) ranging from 12.000 -200.000 Da 
were used to calibrate the column. The procedure for determining molecular weight 
outlined in the Sigma bulletin is a modification o f the methods of Whitaker (135) and 
Andrews (2). Molecular weight determinations o f unknown proteins are made by 
comparing the ratio of V /V u for the protein in question to the V /V 0 o f protein standards 
of known molecular weight (Ve = elution volumetV, = void volume). A calibration 
curve can then be prepared by plotting the logarithms o f the known molecular weights of 
protein standards versus their respective VyV, values. The apparent molecular weight of 
the HTLV-1 protein was calculated from the standard curve (Appendix A) determined by 
calibration of the column with molecular weight standards: blue dextran (Mr =
2.000.000). carbonic anyhydrase (Mr = 29.000). alcohol dehydrogenase (M, = 150.000). 
P-amylase (Mr = 200.000), and cytochrome C (Mr = 12.400).
Table I shows the molecular weights and concentration of markers applied to the 
column. The final concentrations o f each marker, suggested by the manufacturer, would 
give an Also o f approximately 1.0 in the peak fraction. The void volume was determined 
based on the volume of effluent required for the elution of the large molecule, blue 
dextran (Mr= 2.000.000). 2 mL o f 2 mg/mL blue dextran was carefully applied to the 
column. The column was connected to an Econo Pump (Model EP-l.BioRad). an Econo 
UV monitor (Model EM-1. BioRad). an Econo chart recorder (Model 1325. BioRad). and 
a fraction collector (Model 2110. BioRad). To minimize mixing, all pieces o f the 
apparatus connected to the outlet were placed as close as possible to the outlet tubing. 
RTB-50 was pumped through the column at a rate o f 0.5 mL/min to elute the blue 
dextran. The chart recorder, set at 200 mV, I cm/hr, recorded signals from the UV
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TABLE I
Preparation of Protein Standards for Sepharose CL-6B Calibration Curve
Protein Standard Molecular Weight (Daltons) Concentration (mg/mL)'1
blue dextran 2.000.000
P-amylase 200.000 4
alcohol dehydrogenase 150.000 5
albumin 66.000 10
carbonic anhydrase 29.000 j
cytochrome C 12.400 2
JIndividual protein standards were dissolved in RTB-50 containing 5 % glycerol. 
2 mL of individual samples containing the following concentrations, as mg solid per mL 
of buffer, should give an A:so = 1.0 in the peak fraction.
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monitor programmed to read absorbances at 280 nm. The traction collector was set at 8 
mL/tube. This void volume was calculated using the following formula:
cm peak x hr/cm (chart speed) x 60 min/hr x 0.5mL/min (pump speed) = volume (mL) 
migrated
To confirm the void volume, the absorbance of the tubes containing the peak fractions 
and the tubes located before and after the peak were read again manually at 280 nm using 
the department’s Cary UV/Vis Spectrophotometer.
Each of the protein standards was applied as described. The column was allowed 
to equilibrate in 1 L of RTB-50 at 0.5 mL/min between each run. The elution volumes of 
the standards were denoted and the calibration curve (Appendix A) was graphed using 
CA Cricket Graph III Software (Computer Associates).
PURIFICATION OF HTLV-1 REVERSE TRANSCRIPTASE
Unless otherwise indicated, all steps were carried out at 4°C. Each 500 mL bacterial 
pellet was resuspended in 20 mL of STET buffer (50 mM Tris: 8% sucrose: 50 mM 
EDTA and 5% Triton X-100) supplemented with 10 mg/mL lysozyme and a protease 
inhibitor cocktail (Boehringer Mannheim. Atlanta. GA) containing aprotinin. leupeptin. 
pepstatin. phenylmethylsulfonylfluoride (PMSF). antipain, chymostatin, peflabloc and E- 
64. Stock solutions were prepared according to Table II. The bacterial pellet in STET 
solution was kept on ice for I hour. The thawed pellet was vortexed vigorously and DNA 
was sheared with a sonic dismembrator (Fisher Sonic Dismembrator 60) using 4-15 
second pulses. Finally, the suspension was cleared by centrifugation for 30 minutes at 
12.000 RPM to remove insoluble debris. The supernatant from each 500 mL pellet was 
combined to make the 200 mL crude lysate.
Phosphocellulose chromatography o f  HTLV-l RT 
The crude lysate was applied at a flow rate of 0.5 mL/min to a phosphocellulose column 
(20 cm x 5.0 cm i.d.) equilibrated in RTB-50. The column was eluted with an 800 mL 
linear gradient of 0.1 to 1 M K.C1 in RTB-50 supplemented with 10% glycerol (glycerol),
1 mM PMSF and 2 mM dithiothreitol (DTT, Fisher). Fractions o f 8 mL were collected 
and assayed for reverse transcriptase activity as described later in this section.
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TABLE II
Preparation o f Protease Inhibitor Cocktail
Protease Inhibitor Concentration of 
Stock Solution-1
Diluent Buffer Concentration in 
STET Buffer
antipain 50 pM MilliQ water 0.1 pM
aprotinin 76 pM MilliQ water 0.1 pM
ehvmostatin 500 pM glacial acetic acid 1 pM
E-64 1 mM 1:1
H20 /100 % ethanol
I pM
leupeptin 1 mM MilliQ water 1 pM
peflabloc 84 mM MilliQ water 0.4 mM
pepstatin 700 pM methanol 1 pM
PMSF 100 mM 100 % ethanol 1 mM
''All stock solutions were stored as 200-300 pL aliquots in 1.5 mL sterile, eppendorf 
tubes at -20°C.
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Ammonium Sulfate Precipitation 
The fractions containing the majority of enzyme activity were pooled in a 100 mL beaker, 
which was then placed on a stir plate in the 4°C cold box. The pool was precipitated with 
saturated ammonium sulfate (Fisher) to 65 % saturation (0.3432 g/mL; a saturated 
solution = 4 M  (NH4)2S 0 4 = 528 g/L = 0.528 g/mL). The solution was mixed with a 
magnetic stir bar until all o f the ammonium sulfate was dissolved. The pool was 
transferred to a centrifuge tube and centrifuged at 10.000 RPM for 20 minutes. The 
supernatant was discarded and the pellet was resuspended in 1.5-2.0 mL. RTB-50. I’he 
suspension was placed in 12.000-14.000 MW cut-off Spectra/Por® dialysis tubing 
(Fisher) and dialyzed against 1 L RTB-50 for 4 hours. The buffer was changed at 2 
hours. The sample was removed from the dialysis tubing and centrifuged again at 40.000 
RPM for 20 minutes to remove cellular debris.
Sepharose CL-6B chromatography 
The supernatant was loaded on a column (52 cm x 5 cm i.d.) of Sepharose CL-6B. 
equilibrated in RTB-50. The column was developed using the parameters predetermined 
in the calibration procedure. The apparent molecular weight was computed from the 
elution volume of the peak absorbance and the equation for the linear regression line of 
the standard curve was determined by calibration o f the column with molecular weight 
standards: blue dextran (Mr = 2.000.000). carbonic anvhvdrase (Mr = 29.000). alcohol 
dehydrogenase (Mr = 150.000), p-amylase (Mr = 200.000). and cytochrome C (Mr - 
12.400). The peak fractions were also assayed for reverse transcriptase activity as 
described later in the next section.
REVERSE TRANSCRIPTASE ASSAYS
10 pL o f each fraction was pipetted into 40 jaL o f reaction cocktail (final 
concentration: 50 mM Tris-HCl (pH 8.8). 80 mM KC1. 6 mM M gCh, 8 mM DTT.
0.05% Triton X-100. 80 mM dGTP or dTTP (Promega), 1 mM [3H]dGTP (30 Ci/mmol) 
or [3H]dTTP (104 Ci/mmol)(Amersham. Arlington Heights. IL) and 20 jag/mL 
poly(rC)»oligo(dG) template or poly(rA)«oligo(dT) template (Pharmacia), respectively.
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Two control reaction mixtures were also run with each set o f  assays.. The positive 
control contained 10 pL AMV RT and the negative control contained 10 pL sterile water. 
The controls were included as samples for each run. and all samples were run in triplicate. 
Using a timer, start times were staggered 15 seconds apart to give enough time to pipet 
each sample correctly. The reaction mixture was incubated for 1 hour in a 37°C water 
bath. The reactions were terminated by the addition o f 800 pL of 10% trichloroacetic 
acid (TCA. Fisher). Acid precipitable material was collected on Whatman GF/C fiber 
discs, washed with 10 mL of cold 10% TCA and a final wash o f 2 mL of 95% ethanol. 
The filters were loaded into scintillation vials (F isher), 6 mL liquid scintillant (ICN 
Biochemical. Costa Mesa. CA) was added to each vial, and the samples were counted in 
a scintillation counter (Beckman Model LSI701). Background counts due to the reaction 
cocktail were determined by counting 10 pL of reaction cocktail in 6 mL liquid 
scintillation cocktail. The following formula was developed to determine the units of 
specific activity associated with each sample:
_______ CPM of sample________  x (1.5 x 10 ’) pmoles = pmoles activity in the
CPM o f 10 pi o f reaction cocktail sample
There are 1.5 x 10'’ pmoles of [3H]dNTP/10 pL of reaction cocktail.
DETERMINATION OF PROTEIN CONCENTRATION
Protein concentration was determined by the Bradford assay technique using Pierce 
Protein Reagent (Rockford, IL) (14). Bovine serum albumin (BSA) was used as the 
standard. To determine the protein concentration o f reverse transcriptase purification 
samples, protease and Pro-Pol protein purification samples, the 2 mg/mL BSA stock 
solution was used to make a 200 pg/mL BSA working solution in RTB-50 or citrate 
buffer (100 mM sodium citrate. pH 5.3. 5 mM EDTA. 1 M NaCl. and 1 mM DTT). 
respectively. The 200 pg/mL solution was added to a series o f glass, disposable, 
borosilicate test tubes (Fisher) containing MilliQ water to make standards within a 1-25 
pg range. The final volume of each o f  these tubes was 1 mL. Simultaneously, 10-200 pi
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of each purification sample was added to a set of tubes tilled with MilliQ water to a final 
solution volume of 1 mL. To determine the background due to buffer, a control sample 
of 10-200 pL of RTB-50 or citrate buffer was added to MilliQ water to a final volume o f 
1 mL. I mL o f protein assay reagent was added to all o f the standards and the samples. 
The solutions were mixed carefully, and each sample was transferred to a disposable, 
plastic cuvette (Fisher). The absorbance of each standard was read at 595 nm where these 
values were used to create a standard curve using C'A Cricket Graph III Software. The 
absorbance due to the buffer was subtracted from the absorbance o f each sample read at 
595 nm. The difference was applied to the equation for the linear regression line o f the 
standard curve to determine the concentration of the protein alone.
PREPARATION OF SAMPLES FOR SDS-PAGE
To prepare samples for electrophoresis, dilute samples were concentrated by TCA 
precipitation. An aliquot of the fractions and/or pools was placed in a 1.5 mL eppendorf 
tube. The sample was precipitated with a 100% solution of TCA to a final concentration 
of 10% TCA. The tube was vortexed and centrifuged for 5 minutes at 12.000 rpm. The 
supernatant was decanted into a waste beaker and the pellet was washed three times with 
1 mL 95% ethanol. The tube was centrifuged for 5 minutes for each wash and the 
supernatant was discarded as before. The pellet was dried using the Speed Vac and 
resuspended in 20 pL Tricine SDS sample buffer (450 mM Tris HC1. pH 8.45. 12% 
glycerol. 4% SDS. 0.0025% Coomassie Blue G and 0.0025% Phenol Red) or NuPAGE™ 
SDS sample buffer (0.293 sucrose. 141 mM Tris Base, 106 mM Tris HC1, pH 8.5. 69.5 
mM SDS. 0.51 mM EDTA. 0.22 mM Serva Blue G250 and 0.175 Phenol Red). 100 pL 
of P-mercaptoethanoI was added to 1 mL of either sample buffer prior to use. The 
sample was then heated in a 90-100°C heat block for 10 minutes. For concentrated 
samples, samples were mixed 1:1 with sample buffer and heated.
Additionally, the T7 tag positive control (Novagen) was prepared by adding 5 pL 
control sample to 95 pL sample buffer (1:20 dilution). DNA Polymerase I (Promega) was 
prepared by preparing a 1:100 dilution o f enzyme in sample buffer. 15 pL o f these 
particular samples was loaded on the SDS-PAGE where indicated.
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SDS-PAGE
Pools from each step of the HTLV-1 RT purification and fractions from the partial 
purifications o f protease and Pro-Pol protein were analyzed by SDS-PAGE. SDS-PAGE 
was performed as described by Laemmli (59) or by a modification o f the procedure 
described by Schaegger and von Jagow (113). 16% and 18 % acrylamide, Tricine gels 
were prepared according to Table III. Where indicated, some of the SDS-PAGE analyses 
were performed using pre-cast 10-20% acrylamide Tricine gels from Novex (San Diego. 
CA).
The Tricine running buffer was prepared as a I OX stock solution and stored at room 
temperature. 80 mL of the 10X solution was diluted with 720 mL MilliQ water to make a 
IX Tricine running buffer solution (100 mM Tris. pH 8.3. 100 mM Tricine and 0.1 % 
SDS) prior to each run. The acrylamide gel(s) was placed in the Xcell II™ Mini-Cell 
(Novex) apparatus and the IX Tricine running buffer was poured in both the upper and 
lower chambers o f the gel box. The gel was run at a 125 constant voltage for 
approximately 90 minutes using the PowerPac200 (BioRad) power source.
A pre-cast NuPAGE ™ 4-12% Bis-Tris Gel (Novex) with 3-(N-morpholino)propane 
sulfonic acid (MOPS) running buffer was used in the final analysis o f the HTLV-1 RT 
purification. The running buffer was prepared by adding 40 mL of 20X stock MOPS 
buffer (Novex) to 760 mL MilliQ water to give a final concentration o f 50 mM MOPS.
50 mM Tris. pH 7.7. 3.5 mM SDS and I mM EDTA. 500 pL ofNuPAGE™  antioxidant 
(Novex) was added to 200 mL of the running buffer. This solution was poured into the 
upper chamber o f the gel box. The remaining 600 mL of running buffer was poured into 
the lower chamber. The gel was run at a constant 200V for 50 minutes.
After any type o f run was complete, the gel was transferred to a clean glass container 
and pre-washed in 200 mL MilliQ water for 1 hour at room temperature, with rocking. 
The gel was then transferred to another tray filled with 20 mL Gelcode® Blue Stain 
Reagent (Pierce. Rockford, IL) and incubated for 1 hour, with gently rocking. Finally, 
the gel was transferred to another clean glass container and destained in 200 mL MilliQ 
water overnight.
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TABLE III










50% Acrylamide/BIS (29:l)a 2.0 mL 2.25 mL 250 pL
1M Tris-HCl. pH 8.8a 2.35 mL 2.35 mL —
10 % SDSb 62.5 pL 62.5 pL —
0.375 M Tris-HCl, pH 6.8a — — 1 mL
TEMED 1.6 pL 1.6 pL 1.2 pL
50 mg/mL Ammonium 
Persulfatec
156 pL 156 pL 250 pL
50% Sucrose*1 1 mL I mL —
a Acrvlamide and Tris-HCl solutions were made as stock solutions and stored at 4°C. 
bSDS and sucrose were also made as stock solutions and stored at room temperature. 
'■'Ammonium persulfate was prepared fresh for each gel.
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WESTERN BLOTTING
Unless otherwise stated, all steps in the Western blot development procedure were 
performed at room temperature. A second SDS-PAGE gel for transfer was run 
simultaneously with the SDS-PAGE gel that was stained. After electrophoresis, proteins 
in the second gel were transferred to a polyvinylidene difluoride (PVDF. BioRad) 
membrane using a Trans-blot® SD Semi-Drv Electorphoretic Transfer Cell (BioRad). A 
piece of PVDF membrane was cut to approximately the same dimensions o f the gel. The 
membrane was dipped in methanol and then equilibrated in Western transfer buffer (25 
mM Tris Base. 192 mM glycine and 30% methanol) for 30 minutes, with rocking. The 
acrvlamide gel was also equilibrated in buffer for 30 minutes in a separate container.
The gel sandwich was prepared for transfer by placing a pre-wet (with transfer 
buffer) piece o f thick blot absorbant filter paper (BioRad) on the platinum anode. A 
disposable pipet was rolled over the surface of the filter paper to exclude all air bubbles. 
The pre-wetted PVDF membrane was placed on top o f the filter paper. Bubbles were 
removed with the pipet. The equilibrated gel was placed carefully on top o f the 
membrane, aligning the gel in the center of the membrane. Another sheet o f pre-soaked 
filter paper was placed on top o f the gel and air bubbles were removed again. The 
cathode was placed on top of the stack and the proteins on the gel were transferred to the 
membrane at 18V for 50 minutes.
The sandwich was taken apart, layer by layer. If all of the molecular weight 
markers (low molecular weight. BioRad) transferred to the membrane, the blot 
(membrane) was washed with Tris Buffered Saline (TBS. 20 mM Tris. pH 7.5 and 500 
mM NaCl) for 5 minutes. To probe for HTLV-1 RT. the wash was removed from the 
container and the blot was blocked by incubating the blot with 40 mL o f 3% gelatin/TBS 
solution for one hour, with rocking. The blocking solution was removed and the blot was 
washed again with Tween TBS (TTBS; TBS * 0.05% Tween-20) for 5 minutes. The 
wash was again removed and the blot was placed in 40 mL 1% gelatin/TTBS with 5 pL 
ofT 7 tag antibody (Novagen, 1:10.000 dilution) directed against the 10 amino acid gene 
leader sequence peptide expressed by the pET translation vector and incubated overnight 
with gentle rocking.
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The next morning, the antibody solution was removed and the blot was washed 
twice with TTBS. 5 minutes each wash. The washes were removed and the blot was 
incubated with the second antibody solution (40 mL TTBS with 13.2 pL Goat Anti- 
Mouse IgG (H + L) alkaline phosphatase conjugate. 1:3000 dilution. BioRad) for one 
hour, with rocking. The solution was removed and the blot washed twice with TTBS and 
once with TBS. 5 minutes each wash. Detection of the antigen was performed using an 
ImmunoBlot assay kit from BioRad. 300 pL of Color Reagent A (NBT. nitroblue 
tetrazolium in aqueous dimethlyformamide. containing magnesium chloride) and 300 pL 
Color Reagent B (BCTP: 5-bromo-4-chloro-3 indoyl phosphate in dimethylformamide) 
were added to 30 mL alkaline phosphatase color development buffer. After the last TBS 
wash was removed, the blot was developed for 3 hours using the prepared alkaline 
phosphatase color development buffer. Purple bands stained on the blot represent the 
reverse transcriptase protein in the pET translation vector.
The Pro-Pol protein was transferred using the same methods, however, only one 
antibody incubation was required. After transferring the gel. the blot was blocked by- 
incubating the blot with 40 mL of 1% gelatin/TTBS solution for 15 minutes, with 
rocking. The blocking solution was removed and the blot was placed in 25 mL TBS with 
5 pL of S-protein alkaline phosphatase conjugate antibody (Novagen, 1:5.000 dilution) 
directed against the 15 amino acid S-Tag leader sequence peptide expressed by the pET 
translation vector and incubated for 30 minutes with gentle rocking.
The antibody solution was removed and the blot was thoroughly washed 5 times 
with 25 mL TTBS. 1-2 minutes each wash. Detection of the antigen was performed using 
an ImmunoBlot assay kit from BioRad. 332 pL of Color Reagent A (NBT. nitroblue 
tetrazolium in aqueous dimethlyformamide, containing magnesium chloride) and 336 pL 
Color Reagent B (BCIP, 5-bromo-4-chloro-3 indoyl phosphate in dimethylformamide) 
were added to 30 mL alkaline phosphatase color development buffer. After the washes 
were removed, the blot was developed for 15 minutes using the prepared alkaline 
phosphatase color development buffer. Purple bands stained on the blot represent the Pro- 
Pol protein in the pET translation vector.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
41
Color development buffer was removed and the reactions were stopped by rinsing 
the blots with deionized water for 10 minutes, changing the water every 5 minutes. The 
blots were removed from the water and placed on paper towels to dry overnight. The 
next morning, the blot was wrapped in plastic wrap and taped into a laboratory notebook 
for future analysis.
PARTIAL PURIFICATION OF PRO-POL PROTEIN
The two 500 mL bacterial pellets were combined in a 50 mL conical centrifuge tube 
and resuspended in 6 mL of lysis buffer (150 mM NaCl. 50 mM Tris. pH 8.0. 5 mM 
imidazole) supplemented with 0.1% Triton X-100 and ImM PMSF. The solution was 
kept on ice for 1 hour. The thawed pellet was vortexed vigorously and DNA was sheared 
with a sonic dismembrator with 6-10 second pulses and 10 second cooling between 
pulses. The suspension was cleared by centrifugation for 20 minutes at 10.000 RPM at 
4°C to remove insoluble debris. The crude supernatant was used for the subsequent 
purification steps.
V i+--NTA Affinity Chromatography 
Unless otherwise stated, all steps were carried out at room temperature. The crude 
supernatant was incubated, with rocking, with I mL o f N i'2-NTA slurry (Qiagen. 
Valencia. CA). After one hour, the entire solution was poured in a column ( 8 cm x 1.5 
cm i.d.) and the pass fraction was collected. The column was eluted with a stepwise 
gradient o f 5 mL 10 mM imidazole. 5 mL 50 mM imidazole, four 1.25 mL 100 mM 
imidazole washes and 2 mL 500 mM imidazole. Each imidazole wash was prepared in 
buffer containing 150 mM NaCl and 50 mM Tris, pH 8.0). The fractions were analyzed 
by SDS-PAGE. The fractions containing the majority o f the protein were pooled and 
dialyzed against 500 mL lysis buffer (without PMSF and Triton X-100) for four hours, 
where the buffer was changed at the 2 hour interval.
S-tag agarose chromatography 
The entire protein pool from the N i'2 purification step was incubated, with rocking, with 
1 mL S-tag agarose beads (Novagen) for 30 minutes in a 14 mL round bottom, 
polystyrene tube. Recovery o f S-tagged peptide was achieved by following the
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manufacturer's protocol (Novagen). The pass fraction was collected by centrifuging the 
tube, containing the agarose beads and protein, at 500 x g for 10 minutes. The beads 
were allowed to settle and the supernatant was carefully removed with a pipet so as not to 
disturb the beads. The supernatant was transferred to a test tube and labeled as the pass 
fraction. The beads were then washed by resuspending the agarose beads in 5 mL 
bind/wash buffer (50 mM NaCl. 20 mM Tris. pH 8.0. and 0.1% Triton X-100). The 
mixture was mixed by repeated inversion, followed by centrifugation at 500 x g for 10 
minutes. The supernatant was removed with a pipet and transferred to separate test tubes. 
The beads were resuspended twice more in the same manner, and the supernatants were 
saved as low salt washes.
To elute the Pro-Pol protein, the S-protein agarose beads were resuspended in 1.5 
mL 3 M MgCL and the mixture was incubated for 10 minutes, with gentle rocking. A 5- 
mL capacity spin filter, provided by the manufacturer, was placed in a 15 mL sterile, 
centrifuge tube. The incubated mixture was poured into this spin column, fhe bound 
protein was dissociated from the agarose by centrifuging the spin column/centrifuge tube 
assembly at 500 x g for 5 minutes. An additional 1.25 mL of 3 M MgCL was added to 
the spin filter. The assembly was centrifuged again at 500 x g for 5 minutes. A 100 pL 
aliquot of the filtrate was saved for SDS-PAGE analysis while the remainder o f the 
filtrate was dialyzed against 500 mL Bind/Wash buffer for 4 hours using 7.000 MWCO 
dialysis tubing (Pierce). The buffer was changed at two hours. The dialvsate was then 
concentrated 10-fold using an 3.000 MWCO Centricon-3 microconcentrator (Amicon. 
Danvers. MA). The concentrator was placed in a 14 mL centrifuge tube. The dialysate 
was placed in the concentrator/centrifuge tube assembly and centrifuged at 6500 RPM for 
3 hours. The final volume o f the concentrate was 300 pL. Fractions from each step o f 
the purification scheme were analyzed by SDS-PAGE and Western blotting.
EXPRESSION OF ACTIVE PROTEASE
The removal o f  inclusion bodies and the solubilization o f the protease was performed 
using a modified protocol o f a published procedure (19). Briefly, the bacterial pellet was 
resuspended in 1 mL o f buffer A (500 mM NaCl. 20 mM Tris, pH 8.0, 5 mM imidazole).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
43
The solution was kept on ice for 1 hour. The thawed pellet was vortexed vigorously and 
the suspension was centrifuged at 10,000 RPM for 25 minutes. The insoluble fraction 
was resuspended in another 1 mL o f buffer A. vortexed vigorously and centrifuged again 
to further remove inclusion bodies. The insoluble fraction was resuspended in 2 mL 
buffer B (buffer A + 8 M urea) and the DNA was sheared with a sonic dismembrator 
using 6-10  second pulses with a 10 second cooling period between pulses. Finally, the 
suspension was cleared by centrifugation for 20 minutes at 12.000 RPM at 4°C to remove 
insoluble debris. The supernatants from the first two centrifugation steps were saved for 
SDS-PAGE analysis. The final crude supernatant was used for the subsequent 
purification steps.
.Vi+--NTA affinity chromatography 
Unless otherwise stated, all steps were carried out at room temperature. The crude 
supernatant was incubated, with rocking, with I mL of Ni :-NTA slurry. After one hour, 
the entire solution was poured in a column ( 8 cm x 1.5 cm i.d.) and the pass fraction was 
collected. The column was developed with a stepwise gradient o f four I mL 20 mM 
imidazole washes and the protein was eluted with 2 mL of 1 M imidazole. The imidazole 
washes were prepared in buffer containing 500 mM NaCl. 20 mM Tris, pH 8.0. 8 M urea.
Refolding and activation o f  protease 
A 100 pL aliquot of the eluate fraction was saved for SDS-PAGE analysis. To refold and 
activate the protease in the eluate. a sequential dialysis was performed. The protease was 
dialyzed against 500 mL acetate buffer (10 mM sodium acetate. pH 3.5 and I mM DTT) 
for 4 hours using a 3 mL. 7.000 MWCO Slide-A-Lvzen® dialysis cassette from Pierce. 
The buffer was changed after 4 hours, and the protein was allowed to dialvze overnight 
for another 12 hours in acetate buffer. The next morning, the dialysis cassette was placed 
in 500 mL citrate buffer (100 mM sodium citrate. pH 5.3. 5 mM EDTA. 1 M NaCl and 1 
mM DTT). The buffer was changed at the end of the day and the protein was again 
dialyzed overnight. The total acetate dialysis time was approximately 24 hours.
Protease activity assay 
200 pL o f refolded protease was pipetted in a 10 mm quartz cuvette (Stama Cells) and
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incubated for 10 minutes at 37°C in a thermostatically adjusted Luminescence 
Spectrophotometer (Perkin Elmer. Model LS50B). The cuvette was removed from the 
cell chamber and the cleavage reaction was initiated by the addition of 480 pL 100 mM 
sodium citrate buffer and 5 pL substrate( 15 mM). The reaction was mixed by gentle 
inversion and the cuvette was replaced in the cell chamber. Hydrolysis of the synthetic 
substrate Abz-KTKVLVVQPK-(3NO:Y)A (custom made at the University o f 
Michigan), which contains the cleavage site of HTLV-1 p24/pl5 between the underlined 
leucine and valine, was characterized by measuring the fluorescence emission spectra of 
the sample at 450 nm/2.5 nm bandpass at an excitation o f 320 nm/15 nm bandpass. Data 
points were collected over a period o f 30 minutes using FL WinLab Software (Perkin 
Elmer. Norwalk. CT).
IDENTIFICATION OF THE PRO-POL PROTEIN PROCESSING SITE
100 pL o f activated protease in citrate buffer (0.05 pg/pL) was incubated with 
200 pL Pro-Pol protein (0.67 pg/pL) overnight in a 37°C heat block to cleave the Pro-Pol 
protein in lysis buffer. Control samples. 100 uL protease in citrate buffer only and 200 
pL Pro-Pol protein only, were also incubated overnight at 37°C.
Hydrolysis o f the substrate, which contains the putative proteolytic processing site 
at the N-terminus of HTLV-1 RT was analyzed by SDS-PAGE and Western Blotting.
The cleavage reaction samples were separated by SDS-PAGE using either an 18% 
acrvlamide Tricine gel or 10-20% acrylamide gradient Tricine gel. One gel was 
transferred to a PVDF membrane for Western blotting as described previously.
All steps in the following staining procedure were performed at room temperature. 
The second gel was fixed in 100 mL fixing solution consisting o f 50% methanol. 10% 
acetic acid and 40% MilliQ water for 10 minutes, with rocking. The gel was then stained 
using solutions from a Colloidal Blue CoomassierM Staining Kit (Novex). The gel was 
placed in staining solution containing 55 mL MilliQ water. 20 mL methanol and 20 mL 
Stainer A (ammonium sulfate and phosphoric acid) for 10 minutes. 5 mL o f Stainer B 
was added to the staining solution and the gel was allowed to rock for 3 hours. The gel
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was then transferred to a glass tray container with 200 mL MilliQ water and allowed to 
destain overnight.
The entire gel was sealed in a heat-sealable bag. The gel and a Polaroid picture o f 
the gel denoting the band o f interest was sent to the W.M. Keck Biomedical Mass 
Spectrometry Laboratory. Biomolecular Research Facility. University o f Virginia. 
Charlottesville. Virginia. Dr. Nicholas E. Sherman cut the band out o f the gel and 
digested the sample with trypsin. Extracts were combined and evaporated to 25 pL for 
LC-MS analysis.
Mass analysis and sequence analysis 
The masses o f the peptides o f interest from the enzymatic digest were determined by LC- 
MS using a Finnigan LCQ ion trap mass spectrometer system with a Protana nanospray 
ion source interfaced to a self-packed 8 cm x 75 pm i.d. Phenomenex Jupiter 10 pm C18 
reversed-phase capillary column. 0.5-5 mL volumes o f the extract were injected and the 
peptides eluted from the column by an aeetonitrile/0.1 M acetic acid gradient at a flow 
rate o f 0.25 pL/min. The nanospray source was operated at 2.8 kV. The digest was 
analyzed using the double play capability o f the instrument to obtain full scan mass 
spectra and product ion spectra in sequential scans. In this manner, both peptide 
molecular weight and the amino acid sequence was determined. The data was analyzed 
by database searching using the SEQUEST search algorithm. Peptides that were not 
matched by this algorithm were interpreted manually and searched versus the EST 
databases using the SEQUEST algorithm.
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CHAPTER III
RESULTS: PURIFICATION OF RECOMBINANT HTLV-1 RT
Detailed analysis o f the properties o f HTLV-1 RT have been limited by the small 
quantity o f enzyme which can be isolated from retroviral virions. An alternate means to 
prepare the enzyme is to express the pol gene in E. coli. allowing overproduction o f the 
protein and facilitating further characterization. Two clones o f HTLV-1 RT were 
constructed by Dr. Laura Moen (Fig. 5) in our laboratory. Expression o f the full length 
clone in E. coli strain W 311U(DE3) was successful and this protein was used for the work 
described in subsequent sections.
The experimental approach to isolate the recombinant HTLV-1 RT utilized adsorption 
chromatography, a common feature for most polymerase purification procedures.
Proteins bind to the exchanger resins by electrostatic forces. To determine the optimal 
conditions for adsorption, the stability range of the HTLV-1 RT. pH = 7.0-8.0 and its 
isoelectric point (pi) = 9.0 were considered. Scientists suggest using a cation exchanger 
for polymerases that are stable at neutral pH ranges and an anion exchanger for 
polymerases that are more stable at basic pH ranges. For a pi « 8.5. a cation exchanger is 
also recommended (106. 112). Since the HTLV-l RT has an optimum pH within a 
neutral and basic pH range, both a cation exchanger (phosphocellulose; P-l 1) and an 
anion exchanger (diethylaminoethyl cellulose; DEAE) were investigated.
Purification schemes of other reverse transcriptases (HIV-1 RT. BLV RT. AMV RT 
and MMTV) were also analyzed to determine a comparable purification scheme for 
recombinant HTLV-l RT. Phenyl sepharose. heparin sepharose and DNA cellulose 
affinity columns and sepharose gel filtration media were also investigated for fiirther 
optimization o f purification parameters.. All o f these techniques for purification o f 
polymerases utilize a different property o f interaction with the proteins to facilitate 
isolation. Thus, presumptions can be made as to the amino acid composition o f the active 
site o f the enzyme based on the information obtained from each application.
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PRELIMINARY TRIALS
Initially, all trials with each type o f resin were performed using small columns (1 mL 
-50 mL), stepwise gradients and 0.5-1 L bacterial cell pellets. As shown in Appendix B. 
the DEAE cellulose anion exchanger did not fare well with our protein. SDS-PAGE 
analysis and Western blotting indicate that the protein did not stick to the column. The 
majority of the RT activity was found in the pass fraction. SDS-PAGE analysis of a 
phosphocellulose (P-l 1) purification o f the enzyme shows a much cleaner preparation 
compared to the DEAE purification (Fig. 7). Consequently, the DEAE column was not 
considered for the purification scheme.
SDS-PAGE analysis of the P-l 1 purification further indicates that the protein eluted 
at 0.2-0.3 M K.C1 using a stepwise gradient, however, the fractions were not pure. Further 
purification of the protein was attempted by utilizing either a heparin sepharose CL-6B. 
phenyl sepharose CL-4B or DNA cellulose. Each resin was prepared according to the 
manufacturer's instructions and poured as a media slurry in a small column (3-5cm x 1.5 
cm i.d.). Either the 0.2 M or 0.3 M K.C1 fraction from the P-l 1 column was applied to the 
column.
O f the three resins that were investigated, the heparin sepharose gave the best results. 
As shown in Fig. 8A. a high molecular weight protein in agreement with the predicted 
size of the protein eluted in both the 0.1 M and 0.5 M K.C1 fractions. Western blot 
analysis demonstrates that the HTLV-l RT appears only in the 0.5 M KC1 fraction (Fig. 
8B). Earlier efforts to use the heparin sepharose column indicated that the high molecular 
weight protein also eluted in the 0.5 M K.C1 fraction, and this protein was more pure than 
the 0.3 M K.C1 fraction from the P-l 1 step. However, the protein did not appear in the 
Western blot, indicating that the high molecular weight protein was not the HTLV-1 RT. 
To clarify this inconsistency and to determine the concentration at which the HTLV-1 RT 
elutes, a linear gradient o f 0.1-1.0 M KC1 was applied to the column instead o f the usual 
stepwise gradient. Several different peaks o f  RT activity were observed in all o f the 
preparations. Analysis of these peaks by SDS-PAGE and Western blotting proved 
inconclusive as no consistency in gel band patterns could be established. Also, the high 
molecular weight protein did not consistently appear on the Western blot.
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FIG. 7. SDS-PAGE analysis o f a phosphocellulose (P-l 1) purification and a DEAE 
purification. Crude lysate is compared with eluate from each stepwise elution for P-11 
(A) or DEAE (B). The arrow points to recombinant HTLV1-RT.
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FIG. 8. SDS-PAGE analysis of heparin sepharose column fractions. Fractions were 
subjected to electrophoresis on 10% acrvlamide gels and either (A) stained with 
Coomassie Brilliant Blue or (B) transferred to a PVDF membrane for Western blotting. 
The arrow points to the recombinant HTLV1-RT. Coomassie Brilliant Blue or (B) 
transferred to a PVDF membrane for Western blotting. The arrow points to the 
recombinant HTLV1-RT.
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The phenyl sepharose column served two purposes in these preliminary trials: (1) to 
further purify the HTLV-l RT, and (2) to determine if there were any hydrophobic 
regions in the polymerase. Coomassie stained SDS-PAGE gels o f the phenyl sepharose 
fractions indicated that a protein of Mr = 99,000 was present in the 0.6 M- 0 M NH4S 0 4 
fractions yet the protein did not light up on the Western blot (Fig. 9). After repeated cell 
preparations and similar results, it was concluded that the protein may have bound to the 
resin yet becomes too dilute throughout the elution process such that it does not appear on 
the blot. Another E. coli protein may have co-eluted with our protein making the 99.000 
Da band appear concentrated. To evaluate this hypothesis, another preparation was run 
whereby the protein, if present, was eluted off the column with one 0 M NH4S 0 4 elution. 
This pool was concentrated and analyzed by SDS-PAGE and Western blotting. The 
protein band still did not appear in the concentrated fraction. Thus, use o f the phenyl 
sepharose column as a second step for purification of the enzyme was terminated.
The SDS-PAGE analyses of the DNA cellulose fractions did not give any 
encouraging results. Most gels showed that the protein did not stick to the column as the 
protein was found in the pass fraction. Figure 10 also illustrates that the pass fraction is 
not much cleaner than the 0.2 M K.CI fraction from the P-l 1 step.
After performing several preparations, the resin that would optimize purification o f 
the P-l 1 fraction/pool was found to be the gel filtration media, sepharose CL-6B 
(Pharmacia). The overall purification scheme, depicted in Fig. 11. requires a 5 L 
bacterial culture preparation containing the expression plasmid. The protein was eluted 
from a 400 mL P-l 1 column using a linear gradient. The column volumes were 
increased 8-fold from the original 50 mL column in order to recover a sufficient amount 
o f protein for biochemical characterization.
PURIFICATION OF THE RECOMBINANT PROTEIN
The purification procedure, summarized in Table IV. involves only two steps with 
minimum inactivation o f enzyme activity during purification. This procedure results in 
the purification of the recombinant protein to approximately 90% homogeneity (Fig. 12).








|  0.8M 0.6M 0.4M 0.2M
FIG. 9. SDS-PAGE analysis of phenyl sepharose column fractions. Fractions were 
subjected to electrophoresis on 10% acrvlamide gels and stained with Coomassie Brilliant 
Blue. The arrow points to the recombinant HTLV1-RT.
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FIG. 10. SDS-PAGE analysis of DNA cellulose column fractions. Fractions were 
subjected to electrophoresis on 10% acrvlamide gels and stained with Coomassie Brilliant 
Blue. The arrow points to recombinant HTLV1-RT.
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FIG . 11. HTLV-I RT purification scheme. The purification o f the recombinant HTLV-1 
RT involves a two-step chromatographic process involving a cation exchanger, 
phosphocellulose and a gel filtration column, sepharose.
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TABLE IV
Purification o f Recombinant HTLV-1 RT and Associated Activity









£  coli lysate 170 1000 mgb 100 .11
I phosphocellulose 69 856 pg <0.1 24.8
II sepharose 23 33 pg <0.1 3.45
J Bradford Method used (14)
b One unit is the amount of enzyme required for the incorporation of 1 pmole of
labeled dGMP in one hour at 37°C.










FIG. 12. Analysis and purification of HTLV-1 RT by SDS-PAGE. Samples from 
various stages o f the purification were subjected to electrophoresis through a 4-12% Bis- 
Tris gel from Novex and the proteins were detected by staining with Gelcode blue as 
described (2). Lane M. Markers. Lane I. crude ex tract. Lane 2. pooled phosphocellulose 
fraction. Lane 3. sepharose pool. The position o f marker proteins are indicated at the 
sides. The arrow points to the band at the correct size o f the full length translation 
product o f pETab3.
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Phosphocellulose chromatography 
Initially, the bacterial cell pellet containing the recombinant HTLV-1 RT was lysed in 
50mM Tris. 8% sucrose. 50mM EDTA. 5% Triton X-100. 10 mg/mL lysozyme and 
chromatographed on a P-l 1 column. The majority o f  the reverse transcriptase eluted as a 
peak at approximately 0.3-0.5M K.C1 (Fig. 13A). Phosphocellulose chromatography was 
the single most important step in the purification resulting in the greatest increase in 
specific activity: total recovery in this step was. unfortunately, rather low (<0.01%).
Sepharose Molecular Sieve 
The phosphocellulose peak fractions o f  RT activity were pooled and applied to a 
sepharose CL-6B column. By comparing elution volumes of peaks to the standard curve 
shown in Appendix A, it was determined that the RT activity eluted as 2-3 separate peaks 
with varying molecular weights (Fig. 13B). To determine which of these pooled fractions 
contains the recombinant protein, samples from the protein fractions were analyzed by 
SDS-PAGE. and the proteins were visualized by staining with either Coomassie or 
Gelcode Blue. A major band (Mr = 82.000-104.000) was found in the third sepharose 
pool (Fig. 12). Since the location o f the band in the gel is in agreement with the 
estimated size o f  our protein and has the expected activity, the pool was concentrated for 
further analysis.
STABILITY STUDIES
Figure 14A shows a comparison o f the activities o f  pooled fractions at different stages 
of purification. A 60-fold increase in RT activity was consistently observed after the 
cmde extract was passed through the phosphocellulose column. However, by the time 
the sepharose fractions (eight days) were pooled and recovered, the protein had lost 80- 
90% of its activity.
Time and Temperature 
To determine whether the activity loss was due to the temperature conditions at which the 
samples were stored or if the activity loss was solely due to the duration o f time that had 
passed, aliquots o f the sepharose pools were stored at three different temperatures: 4°C. 
20°C and -80°C. No significant difference in activity was calculated when sepharose
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FIG. 13. Purification elution profiles. (A) Phosphocellulose elution profile. The crude 
extract was chromatographed on P-l I (20 x 5 cm i.d.) as described in the text. Activity 
o f fractions (■) was determined over the range o f fractions eluted with a linear gradient 
( • ) .  The arrow indicates the fractions containing the recombinant protein. (B) Sepharose 
elution profile. The concentrated P-l I pool was applied to a sepharose 6CL-B column 
(52 x 5 cm i.d.). Aliquots o f individual fractions were assayed for reverse transcriptase 
activity as described in Materials and Methods. The arrow indicates peak activities at (I) 
640 kDa, (II) 540 kDa and (III) 99 kDa.
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FIG. 14. Template and stability studies. RT activity was assayed as described in 
Materials and Methods. Black boxes represent poly(C)«oligo(dG) template. Gray boxes 
represent poly(A)*oligo(dT). (A) Stability over time was tested as described on 10 pL 
samples from each stage of purification. (B) Aliquots of the sepharose pool were stored 
at three temperatures: 4°C, -20°C and -80°C.
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samples were stored at different temperatures (Fig. 14B). This pattern appears to be time 
dependent and was seen at all stages o f purification. The addition or elimination o f 
reducing agents did not have any effect on the rate o f activity loss. Activity could not be 
recovered by reconstitution with the other sepharose pools.
To enhance the stability o f the P-l 1 pool before the pool is applied to the sepharose 
column, complete dehydration of the P-l 1 pool by speed vacuum drying or lyophilization 
was suggested. Aliquots o f the P-l 1 pool were either dried using the speed vacuum in 
our laboratory or shell-frozen in liquid nitrogen and lyophilized at Eastern Virginia 
Medical School. The aliquots were then stored at -70°C. The samples were reconstituted 
in RTB-50 and RT activity was measured over a period of one week.
Figures 15 and 16 compare the RT activity of a P-l 1 pool stored at the same 
temperatures investigated earlier as well as speed vacuumed and lyophilized samples.
The graphs illustrate that P-l 1 pools are not stable in any particular storage condition. In 
Fig. 16. the P-l 1 pool dropped to 67% o f the original activity when speed vacuumed dry. 
The sample that was frozen in liquid nitrogen and stored at -70°C dropped similarly to 
72% of the original activity. As expected, almost all samples dropped in activity after a 
week's time had passed. In some cases, activity dropped to almost 30% o f the P-l 1 pool 
activity. In other preparations, this decrease was not seen at all which adds to the overall 
inconsistency of storage conditions. Results of this study indicate that perhaps the 
protein's activity is intrinsically low or that the protein exists in an unfavorable folded 
state. These speculations will be farther addressed in a subsequent section.
TEMPLATE SPECIFICITY
As shown in Figs. 14A and 16. reverse transcriptase activity was also investigated 
with three synthetic homopolymeric templates. poly(rA)«oligo(dT), poly(rC)»oligo(dG) 
and poly(dA)«oIigo(dT). In earlier studies o f template specificity, only 
poIv(rA)«oligo(dT) and poly(rC)«oligo(dG) were analyzed. The recombinant protein 
does not have a strong preference for either synthetic template (Fig. 14A). However, the 
recombinant protein in the phosphocellulose pool did prefer the poly(rA)*oligo(dT)
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FIG. 15. Stability of P-l 1 pools. RT activity of P-l 1 pools stored at different 
temperatures and conditions was measured. After the P-l 1 pool was dialyzed, it was 
stored in 50 pi aliquots at various temperatures.
















SPEED VAC N2 & SPEED VAC
FIG. 16. Re-examination of the stability of the P-l 1 pool. Another P-l 1 preparation 
was further analyzed to assess its stability when stored as a speed vacuumed sample 
a liquid N2 frozen sample. Shaded boxes represent poIy(C)«oligo(dG) template. Open 
boxes represent poly(A)«oligo(dT).
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template over the poly(rC)«oligo(dG) with a 3-fold increase in nucleotide polymerization 
(Fig. 14A). Analysis o f crude extracts carrying the plasmid by polyacrylamide gel 
electrophoresis (Fig. 12) indicated that many proteins were being synthesized that could 
contribute to the activity o f  the protein. The increase in activity was attributed to cellular 
polymerase interference, particularly E. coli Pol I. which has a greater affinity for the 
poly(rA)»oIigo(dT) template.
E. coli DNA POLYM ERASE I
Other research reports have confirmed that highly purified DNA polymerase I of 
E. coli. when presented with a polv(rA)«polv(dT) template, can form poly (dT) with a 
high efficiency (5. 51. 100). Furthermore. poly(rA)»poly(dT) is an equally effective 
template for both viral and cellular DNA polymerases, and therefore cannot be used to 
distinguish reverse transcriptase activity from that o f other DNA polymerases (101). In 
contrast, when the same group tested the synthetic oligomer-homopolymer templates, 
such as po!y(rA)*poly(dT) and po!y(dA)*poly(dT). the viral reverse transcriptase could 
clearly be distinguished from the cellular DNA polymerase. The AMV RT and Mason- 
Pfizer monkey virus (M-PMV) showed a preference for the polv(rA)«poIy(dT) while the 
E. coli DNA Pol I showed a preference for the poly(dA)«poly(dT) template.
As previously stated, the recombinant HTLV-1 RT did not show any template 
specificity when comparing synthetic hybrid templates. The increase in activity seen in 
the P-l 1 pool while using the poly(rA)*polv(dT) template may be due to interferences 
from the E. coli DNA Pol I. Moreover, E. coli DNA polymerase has an approximate Mr 
= 109,000 Da. In Fig. 12. the recombinant HTLV-1 RT protein appears between the 87 
kDa and 120 kDa molecular weight markers. Since SDS-PAGE provides a relative 
estimation o f molecular weight, it is possible that the E. Coli DMA polymerase was 
purified, not the HTLV-1 RT, which may explain the increase in activity in the P-l 1 pool 
and decrease in the sepharose pool. To examine this possibility, the high template 
specificity o f E. coli DNA Pol I for a poly(dA)«poly(dT) template was confirmed by 
making serial dilutions o f  pure E. coli DNA Pol I (Promega). The polymerase activity o f
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each dilution was measured using three templates: poly(rA)«oligo(dT), 
poly(rC)*oligo(dG) and poly(dA)»oligo(dT). Figure 17 illustrates that E. coli DNA Pol I 
has a high specificity tor a poly(dA)«oligo(dT). The polymerase activity with this 
template is a 5-50-fold increase o f the activity obtained from a poly(rC)*oligo(dG) 
template. With every subsequent preparation, activity assays were performed using both 
of these templates. The ratio o f activity of poly(dA)«oligo(dT)/ polv(rC)«oIigo(dG) of 
subsequent preparations was approximately 1.1-1.5 indicating that most likely the activity 
seen in the different purification steps is from the recombinant HTLV-l RT.
To further confirm that the protein isolated was HTLV-l RT. the migration 
pattern o f a 1/100 dilution of E. Coli DNA Pol 1 was analyzed on an SDS PAGE gel and 
compared to the migration pattern o f purified HTLV-l RT. Figure 18 illustrates that the 
E.coli DNA Pol I does indeed migrate at a higher molecular weight than the recombinant 
HTLV-l RT protein. Further analysis by Western blotting indicated that there was no 
cross reactivity with the T7 tag antibody. The E. coli DNA Pol I enzyme did not appear 
in the Western blot.
Still, the stability issue has not been resolved. The protein may not maintain its 
native, active form due to improper folding of the enzyme. The N-terminus o f the reverse 
transcriptase may play a role in the proper folding of an active enzyme. For example, in 
HIV-1 RT. the 20 amino-terminal amino acids are absolutely required for its 
polymerization activity (42). Therefore, by identifying the authentic N-terminus of the 
HTLV-l RT. a basis for the structural analysis o f the enzyme can be established. Further 
investigation o f the correct N-terminus would allow for a better understanding of folding 
differences that may explain the low stability of the enzyme.
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FIG. 17. Activity assay of E. coli DNA Polymerase I. Pure E. coli DNA Pol I 
(Promega) was diluted in RTB-50: 1:10,000; 1:1,000; 1:100, 1:10; 1:5. The polymerase 
activity was measured for each diluted sample using three different templates: 
poly(rA)«oligo(dT), poly(rC)«oligo(dG) and poly(dA)*oligo(dT).
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28kD  *
FIG. 18. SDS-PAGE analysis o f E. coli DNA Polymerase I. Fractions were subjected to 
electrophoresis on a 16% Tricine gel and stained with Gel Code Blue. (A) Lane M. 
Markers. Lane 1, DNA Pol 1 (B) Lane M. Markers. Lane 2. concentrated sepharose pool. 
The position of marker proteins are indicated at the sides. The black arrow points to E. 
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CHAPTER IV
RESULTS: IDENTIFICATION OF THE N-TERMINUS
OF HTLV-l RT
Translation o f the retroviral reverse transcriptases in the pol region is a complex 
process because of the occurrence o f frameshift events. The first reading frame o f the 
genomic RNA encodes for the Gag protein. The first frameshift event results in a Gag- 
Pro polyprotein precursor. In some retroviruses, such as BLV. a second frameshift occurs 
resulting in the synthesis o f a Gag-Pro-Pol polyprotein precursor. These precursors must 
be cleaved by viral protease to produce the Pol related enzymes (16, 151).
Little is known about the cleavage sites o f HTLV-l protease, particularly in the 
pol region. HTLV-l is closely related to HTLV-2 and BLV, and their sequences show a 
high degree of homology at the DNA and protein level (52, 84). Perach et al. determined 
the amino terminus o f BLV RT matches the last 26 codons o f the pro gene and is coded 
for by the pro reading frame (92). As discussed earlier. HTLV-l also uses two successive 
frameshifts to form its Pol polyprotein. Thus, an analogous cleavage position in the Pro- 
Pol precursor would create a Pol protein with the first 25 amino acids being derived from 
the protease reading frame.
Published alignments between the protein sequences o f the reverse transcriptases 
o f HTLV-l and HIV-1 (52) begin the comparison at the first amino acid after the pro-pol 
frameshift in HTLV-l at a position 27 amino acids downstream from the known amino 
terminus o f HIV-1 RT (25, 61). However, an alignment beginning at the first N-terminal 
amino acid o f HIV-1 RT with the proposed HTLV-l coding sequence which includes the 
extra 25 amino acids from the pro ORF shows significant similarity. Figure 6 shows this 
homology comparison and includes equivalent regions from both HTLV-l and BLV as 
well. Thus, based on the above evidence, the amino terminus o f HTLV-l RT is believed 
to be amino acid number 158 at the pro ORF (100), 25 amino acids upstream o f the 
frameshift into the pol ORF. This cleavage site corresponds to Leul57-Pro158 in the pro  
ORF.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
67
To identify the authentic amino terminus of the HTLV-l RT. Dr. Laura Moen 
constructed a clone using the same strategy as that used to clone the HTLV-l RT (Fig. 5) 
to produce a protein fragment composed of the amino acids from the C-terminal region of 
the protease up through the amino acids in the frameshift region of the pol ORF. The 
Pro-Pol protein is approximately 11,700 Da and contains the region tentatively identified 
as the cleavage site based on the sequence alignments (Fig. 19).
PREPARATION OF SAMPLES FOR CLEAVAGE ASSAY
Partial purification o f  the Pro-Pol protein for the cleavage assay 
The protein was partially purified using a N i': affinity column and an S-tag agarose resin 
as described in the methods section. As shown in Fig. 20A, the majority of the Pro-Pol 
protein eluted in the 50 mM imidazole and the first two 100 mM imidazole washes.
These fractions were further purified with S-tag agarose to approximately 70% 
heterogeneity (Fig. 20B. lane 6).
Refolding and activation o f  protease 
Before the HTLV-l protease clone could be utilized for processing of the Pro-Pol 
protein, it was first refolded and activated in low pH buffers. The HTLV-l protease 
functions as a dimer, composed of two identical monomeric subunits. Each monomeric 
subunit has a Mr= 14.000. In vivo, protease activation occurs via excision of the protease 
monomer from the Gag-Pro precursor followed by dimerization of the monomeric units. 
Dimerization is essential for its enzymatic activity (39). The protease construct was 
partially purified following an already published procedure for in vitro activation (19). 
The sequence for the protease construct is depicted in Appendix C. As shown in Fig. 21. 
the expressed protease construct migrated at a higher molecular weight (Mr=28.000) than 
the weight predicted for the monomer. This occurrence can be attributed to the histidine 
tag which carries a positive charge. The massxharge ratio becomes altered resulting in 
the slower migration o f  the protein. Still, the protease was expressed in both the 
insoluble precipitate in the dialysate and the supernatant (lanes PPT and R). The size of 
this expression product suggests that the protease did not completely autoprocess (i.e. the 
histidine tag was not completely processed during dialysis), yet, protease activity
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10 20 30 40
ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC CAG CAC ATG GAC 
TAC TTT CTT TGG CGA CGA CGA TTT AAG CTT GCG GTC GTG TAC CTG 
Met Lvs Glu Thr Ala Ala Ala Lvs Phe Glu Arg Gin His Met Asp
50 60 70 80 90
AGC CCA GAT CAG GGT ACC CTG GTG CCA CGC GGT TCC ATG GCC ATC 
TCG GGT CTA GTC CCA TGG GAC CAC GGT GCG CCA AGG TAC CGG TAG 
Ser Pro Asp Gin Gly Thr Leu Val Pro Arg Gly Ser Met Ala lie
100 110 120 130
ATA GGT CGT GAT GCC TTA CAA CAA TGC CAA GGC GTC CTG TAC CTC 
TAT CCA GCA CTA CGG AAT GTT GTT ACG GTT CCG CAG GAC ATG GAG 
lie Gly Arg Asp Ala Leu Gin Gin Cvs Gin Gly Val Leu Tvr Leu
140 150 160
CCT GAG GCA AAA GGG CCG CCT GTA ATC TTG 
GGA CTC CGT TTT CCC GGC GGA CAT TAG AAC 
Pro Glu Ala Lvs Glv Pro Pro Val lie Leu
170 180
CCA ATA CAG GCG CCA 
IGGT TAT GTC CGC GGT 
Pro lie Gin Ala Pro
190 200 210 ' 220
GCC GTC CTT GGG CTA GAA CAC CTC CCA AGG CCC CCC GAA ATC AGC
CGG CAG GAA CCC GAT CTT GTG GAG GGT TCC GGG GGG CTT TAG TCG
Ala Val Leu Glv Leu Glu His Leu Pro Aru Pro Pro Glu lie Ser
230 240
CAG TTC CCT TTA AAC
GTC AAG GG 
Gin Phe Pro
250 260 270
CCA GAA CGC CTC CAG GCC TTG CAA CAC TTG 
GGT CTT GCG GAG GTC CGG AAC GTT GTG AAC 
Leu Asn Pro Glu Arg Leu Gin Ala Leu Gin His Leu
A AAT TTG
280 290 300 310
GTC CGG AAG GCC CTG GAG GCA GGC CAT CTC GAG CAC CAC CAC CAC 
CAG GCC TTC CGG GAC CTC CGT CCG GTA GAG CTC GTG GTG GTG GTG 
Val Arg Lvs Ala Leu Glu Ala Glv His Leu Glu His His His His
320
CAC CAC TGA 
GTG GTG ACT 
His His ***
FIG. 19. Amino acid sequences of the HTLV-l Pro-Pol protein. The Pro-Pol protein 
sequence spans a region where the HTLV-l protease is known to terminate. Isol,:-Leu15
(86), and continues past the pro-pol frameshift site. (-----) dotted lines represent the
putative cleavage site. Boxed amino acid sequence represents the region o f the second 
frameshift.
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FIG. 20. Analysis of the purification steps of the Pro-Pol protein by SDS-PAGE. (A) 
Ni’:-NTA affinity fractions of the Pro-Pol protein purification were subjected to 
electrophoresis through a 16% Tricine gel and the proteins were detected by staining with 
Gelcode blue. Lane 1. crude extract. Lane 2. pass. Lane 3. 10 mM imidazole wash.
Lane 4. 50 mM imidazole wash. Lanes 5-8. 4 sequential 100 mM imidazole washes.
Lane 9. 500 mM imidazole eluate. (B) The 50 mM and the first two 100 mM imidazole 
washes o f the Pro-Pol protein NT2 purification were pooled, dialvzed and incubated with 
S-tag agarose. Fractions were subjected to electrophoresis through a 16% Tricine gel and 
the proteins were detected by staining with Gelcode blue. Lane 1. N i'2 dialvsate. Lane 2. 
pass. Lanes 3-5. sequential low salt washes. Lane 6, concentrated MgCL eluate. Lane 
M, molecular weight markers. The position of marker proteins are indicated at the sides. 
The arrow points to the band at the correct size o f the Pro-Pol protein.
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FIG. 21. Purification o f histidine-linked HTLV-l protease on Ni‘:-NTA agarose. Lanes 
AI and A2. 1st and 2nd Buffer A washes, respectively. Lane B. supernatant from Buffer 
B wash. Lane P. pass. Lanes 1-3. 20 mM imidazole washes. Lane E. 1 M imidazole 
eluate. Lane PPT. resuspended precipitate formed during dialysis. Lane R. refolded and 
activated protease. Lane M. molecular weight markers. The position of marker proteins 
are indicated at the sides. The arrow points to the histidine-linked protease.
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measurements o f  the supernatant dialysate demonstrate that the protease is still active 
with a specific activity =1.3 AAU p.L/pg«sec (Fig. 22). Contrary to the findings o f Ding 
et al. (20). most o f the activity was found in the supernatant, not the white precipitate 
(data not shown). However, our data does support the fact that the incomplete processing 
of the histidine tag from the protease fusion protein does not interfere with the activity of 
the enzyme (20).
CLEAVAGE PRODUCT ANALYSIS
Months before the partial purification scheme o f the Pro-Pol protein was 
established, HPLC analysis was attempted to separate the N i': affinity pool using a 
reverse phase C 18 column. In using HPLC analysis. Pro-Pol protein, protease and 
cleavage product peaks could be separated and evaluated individually. Regretfully, the 
protein could not be recovered in an adequate quantity and the investigation was 
terminated.
Fortunately, cleavage analysis o f the Pro-Pol protein does not require the protein 
to be pure and the Pro-Pol protein from the N i': step and the final S-tag purification step 
were cleaved with active protease. After an overnight incubation of the Pro-Pol protein 
with activated protease, the samples were analyzed by SDS-PAGE. Figure 23A shows 
the results o f the cleavage of the protein by the protease. The Pro-Pol protein appears as 
a 12,000 Da band and the active protease appears as a 28,000 Da band. A diffuse protein 
band at an approximate Mr=5.500. which was suspected to be a fragment of the processed 
Pro-Pol protein, only appears in the lane corresponding to the sample taken from the 
cleavage reaction. The molecular weight o f the entire Pro-Pol protein is approximately 
11,700 Da. Hydrolysis by HTLV-l protease at the putative cleavage site between Leu55 
and Pro56 (numbered according to the amino acid sequence o f the Pro-Pol protein) would 
produce 5.700 Da and 6.000 Da fragments. As shown in Fig. 23B. these same cleavage 
samples were analyzed by immunoblotting with an antibody alkaline phosphatase 
conjugate directed against the N-terminal 15 amino acid S-tag leader sequence fused to 
the Pro-Pol protein. As shown in lane 2, the Pro-Pol protein construct reacted with the 
antibody to give a band corresponding to the Mr = 12 kDa expected for the peptide.











200 400 600 800 1000 1200 1400 1600 1800
tim e (seconds)
FIG. 22. Activity o f protease produced from the insoluble IK 19 construct. 200 pL of the 
dialysate o f the IK.19 protease construct was incubated in the presence o f a fluorescent, 
synthetic substrate, in 100 mM sodium citrate buffer. pH 5.3. Excitation wavelength was 
set at 320 nm/15 run bandpass.
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Fig. 23. Processing o f the Pro-Poi protein from the concentrated S-tag eluate by HTI.V-I 
protease. Partially purified peptide samples were incubated with activated protease 
overnight at 37°C. (A) SDS-PAGE was carried out as described in Materials and 
Methods using a 10-20 % acrylamide gel which was stained with colloidal Coomassie 
Blue, or (B) analyzed by Western blotting with an S-tag antibody alkaline phosphatase 
conjugate. Lane 1, protease only control. Lane 2. Pro-Pol protein only control. Lane 
cleavage reaction sample. Lane M, markers. The position of marker proteins are 
indicated at the sides.
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Similarly, both the 12 kDa band and the 5.5-kDa band were detected in the cleavage 
product sample (Fig. 23B. lane 3). Neither the 12 kDa band nor the 5.5-kDa band was 
detected in the protease only sample (Fig.23B, lane 1).
PROTEOLYTIC PROCESSING SITE ANALYSIS BY TRYPSIN DIGESTION 
AND MASS SPECTROMETRY
To identify the location of the proteolytic processing site of the N-terminus o f the 
HTLV-l RT. several lanes were loaded with cleavage samples and a Pro-Pol protein 
only sample on an 18% Tricine gel. The gel was stained with Colloidal Coomassie Blue 
and sent to the Biomolecular Research Facility at the University of Virginia in 
Charlottesville. Virginia (Fig. 24). Dr. Nicholas Sherman removed the 5.5 kDa band, 
digested it with trypsin, and the peptides were analyzed by mass spectrometry. Since 
trypsin cleaves at the C-terminal side o f lysine and arginine residues (26), a list o f 
possible peptides was generated from a hypothetical tryptic digestion of the Pro-Pol 
protein sequence as shown in Table V. A summary of the seven fragments actually 
recovered from the tryptic digestion o f the 5.5 kDa fragment is shown on the right-hand 
side o f Table V. The actual spectra can be found in Appendix D. Five of the seven 
peptides obtained from the tryptic digest o f the cleavage fragment matched those o f the 
peptides calculated from the SEQUEST algorithm. Peptides 1 and 2 correspond to 
sequences at the N-terminus of the Pro-Pol protein, while peptides 6 and 7 correspond to 
sequences at the C-terminus.
Isolation of only one fragment o f the Pro-Pol protein was expected to produce either 
C-terminal or N-terminal peptides upon tryptic digestion. The fact that both N-terminal 
and C-terminal peptides were obtained indicates the presence o f two protein bands, which 
were previously identified as a single Pro-Pol protein fragment migrating at a distance of 
5.500 Da. The total molecular weight o f the peptides found in the actual tryptic digest is 
approximately 10,700 Da. almost twice the molecular weight o f the band that was 
digested. Thus, analysis confirms that the diffuse band at Mr =5.500 Da was indeed the 
two fragments o f  the Pro-Pol protein predicted by cleavage at or near the proteolytic 
processing site identified by the sequence alignment.
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FIG. 24. SDS-PAGE gel sent for MS analysis. A 10-20 % acrylamide gel o f cleavage 
samples either (A) stained with colloidal Coomassie Blue or (B) analyzed by Western 
blotting with an S-tag antibody alkaline phosphatase conjugate. Lane I, Pro-Pol protein 
only control. Lane 2, protease only control. Lanes 3-10, cleavage reaction samples. 
Lane M, markers. The position o f marker proteins are indicated at the sides.
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Glu3-Lys8 590.7 ETAAAK 1 1581.2 +3 QHMDSPDQGTLVPR
Gin12-Arg25 1581.8 QHM DSPDQGTLVPR 2 820.3 +2 GSM(o)AHGR
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The identity o f the cleavage site location was determined by examination o f 
peptides 4 and 5. neither o f which matches any of the predicted peptides in Table V. The 
mass spectra were determined manually. As shown in Figure 19. these peptide sequences 
are located in the middle of the pro-pol amino acid sequence. The C-terminus o f 
peptide is Leu3'while the N-terminus o f peptide 5 is Pro36. Cleavage at this position 
could not have occurred by trypsin digestion since no lysine or arginine residues are 
present.




The collaborative activity o f the protease. reverse transcriptase and integrase enzymes 
during retroviral replication ensures the survival o f the virion. The reverse transcriptase 
catalyzes transcription o f viral RNA into double-stranded DNA. which is later 
incorporated into the host to form the provirus. Structural information obtained about the 
reverse transcriptase could aid in the development o f antiviral therapeutic agents aimed at 
inhibiting the early onset of replication.
Unlike other retroviruses, little is known about the structure or proteolytic processing 
of the reverse transcriptase o f the human T-cell leukemia virus. In large part, this is due 
to the fact that little reverse transcriptase is produced from the virus. The availability of 
methods to express foreign genes in E. coli facilitates isolation o f large quantities of 
recombinant reverse transcriptase. Although larger amounts of total protein are recovered 
by this method, the catalytic amount o f product still does not support serious biochemical 
or biophysical investigations.
Two reports have been published on the expression o f recombinant HTLV-l RT. In 
the first. Owen et al. expressed an enzymatically active HTLV-l RT in bacteria, and their 
clone was created such that translation was initiated at Pro”. which is located within the 
proposed pro-pol frameshift site (91). In the second report. Trentin et al. hypothesized 
that the N-terminus of the RT should immediately follow the known C-terminus of the 
protease (131). The resulting protein from their construct also had RT activity (13). 
However, they used an in vitro transcription/translation system that may have had an 
impact on overall folding and potential subunit structure. Taken together, there are 
discrepancies between the two published reports on recombinant HTLV-l RT. 
Furthermore. Perach et al. (92) found that the amino acid sequence requirements and 
molecular arrangements o f the recombinant BLV RT. the closest relative to HTLV. are 
substantially different from those of both HTLV-l RT studies. Here, a recombinant
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enzyme was also expressed in E.coli to further address the biochemical properties o f 
HTLV-I RT as well as functional aspects of protein-nucleic acid interactions.
By using sequence similarities with other retroviral reverse transcriptases in 
conjunction with information about the location of the ribosomal frameshift. our 
laboratory has cloned the correct coding region for the HTLV-l reverse transcriptase. To 
our knowledge, this recombinant protein is the first reverse transcriptase activity 
expressed from the CH strain o f HTLV-l.
In summary, a virtually homogenous, recombinant HTLV-l RT was separated from 
E. coli proteins and enzyme degradation products by using a two-step chromatographic 
technique. The purification scheme enhanced the presence o f the 99kDa band on SDS- 
PAGE that corresponds to the predicted molecular weight o f  the recombinant protein.
The size and activity o f the recombinant enzyme agree with the only published studies on 
the protein purified from virus-infected human cell lines (101). Although the 
recombinant protein is not stable for long periods of time, it does maintain reverse 
transcriptase activity throughout the purification process.
The purified recombinant HTLV-l RT was further characterized to determine its 
primary structure. The primary structure o f proteins/peptides includes the determination 
o f the linear order o f the amino acid residues, plus, any covalently attached groups and 
the accurate measurement o f the protein's molecular weight. To date, the amino terminal 
sequence of the polymerase gene o f HTLV-l. which encodes the reverse transcriptase, 
had not been determined. The amino terminus of the reverse transcriptase may play a 
role in the proper folding of an active enzyme. For example, in the HIV-1 RT. the 20 
amino-terminal amino acids are absolutely required for its polymerization (42).
Therefore, to confirm that the purified HTLV-l RT protein has the authentic N- 
terminus. identification o f the proteolytic processing site of the Pro-Pol precursor protein 
was determined. In the virion, the reverse transcriptase is released from the larger 
polypeptide precursor by proteolytic cleavage. To mimic this proteolytic processing event 
in vitro, the pro-pol cD N A , which spans the region where the HTLV-l protease is known 
to terminate and continues 19 amino acids past the pro-pol frameshift, was cloned and 
expressed in E. coli. The sequence o f the Pro-Pol protein contains a portion of the larger
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Pro-Pol precursor and the putative protease cleavage site. Using an active HTLV-l 
protease construct (Fig. 22), The protein was cleaved to produce a 5,500 Da cleavage 
fragment (Fig. 23). LC/MS and MS-MS analysis of the cleavage fragment revealed that the 
HTLV-l protease cleavage site which generates the N-terminus o f mature HTLV-l RT is 
located between L e u  ^ ”7 ancj P ro^S  jn ^  pro q r f  (82). 25 amino acids upstream of the 
pro-pol frameshift. This cleavage site does not differ from other retroviral processing 
sites in the pol region (Table VI). which suggests that retroviral proteases preferentially 
process their substrates at specific cleavage sites (20). The cleavage site is in agreement 
with the sequence alignment perform by our group and by Trentin et al.(131).
Still, activity o f the purified enzyme is low (3.45 U/pg). Further efforts directed 
towards improving the enrichment and optimal activity of the enzyme were not 
successful. However, the low levels of activity observed are in agreement with those 
reported by others (91). The overall inconsistency in activity measurements observed in 
these different purification preparations may indicate that the RT activity o f HTLV-l in 
and o f itself is low. or perhaps the presence of the T7 tag may have disrupted the 
favorable native conformation of an active enzyme. Trentin et al. suggest that the 
structure o f  the HTLV-l RT is complex and thus a more detailed structural analysis is 
necessary (131).
The low RT activity observed in this project provides useful information about the 
biology o f the lymphotropic viruses. Reverse transcriptases lack editing functions and 
have been shown to be error-prone in vitro. Therefore, these enzymes are presumed to 
contribute to the high mutation rate in vivo (52). The frequency o f  RT errors is dependent 
on the source of RT. For example, the error rate o f HIV-1 RT ranges from 1 in to 4000 
7000 (per genome per cycle) while the error rates of ASLV and MuLV are I in 9000 to 
17.000 and 1 in 30.000. respectively (98. 104). This high level o f  infidelity may be a 
common characteristic o f RNA tumor virus reverse transcriptases.
High error rates in DNA replication result in genetically diverse populations of 
viruses. However, HTLV-l shows minimal strain variation in comparison to a much 
greater variation seen among different isolates o f each lentivirus in the HTV/SIV family (28, 
30, 57, 61, 77). Ratner et al.reports a 1.2%-3.3% nucleotide sequence difference among
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HTLV-l isolates (97). The low activity of the HTLV-l RT and apparent differences in 
mutation rates may explain the genomic stability and replication mechanism of HTLV-l.
Unlike the HTLV-l RT. HIV-1 RT is highly stable and has a much higher activity 
(273.9 pmoles/pg/hr) in the presence of a polv(rC)*oligo(dG) template (12). Chandra et al. 
further reports the V,nax for HIV-l RT is seven-fold higher than the HTLV-l RT (12). Thus. 
HIV-1 replicates persistently at a high level and quickly develops extensive within-isolate 
sequence variation. It can be concluded, then, that there is little persistent replication of 
HTLV-l because the RT activity is low. Wodarz et al. suggests that the high viral load that 
does exist during HTLV-l infection (0.1-10% of peripheral blood mononuclear 
lymphocytes), then, is maintained largely by division of pro virus-containing cells (145). In 
short, the virus must rely on another replication mechanism, the mitotic route, to ensure its 
survival. Wodarz et al. hypothesizes that mitotic division rather than infectious 
transmission o f the virus produces most of the newly infected cells. The mitotically 
transmitted provirus is subsequently replicated by cellular DNA polymerases. The low 
mutation rates o f HTLV-l are due to the proofreading capability o f cellular DNA 
polymerases (145).
The results o f this research project have provided a basis for future structural 
characterization o f retroviral reverse transcriptases. Tasara. et al. found significant 
contributions of both the N- and C- termini o f the HIV-1 RT p51 subunit to the structural 
and functional conformation of the p66 subunit, hence, the activity of the HIV-1 RT 
heterodimer (129). These regions contribute significantly to the maintenance of the 
optimal conformation between the DNA polymerase and RNaseH catalytic sites o f  the 
p66 subunit. The authentic N-terminus o f HTLV-I RT was determined and confirmed in 
this project. This information will. likewise, lead to a better understanding of the protein- 
nucleic acid interactions o f this class o f enzymes. This research has also provided a basis 
for future studies aimed at comparing the replication pathways addressed previously which 
would lead to an increased understanding of the pathogenesis o f HTLV-l induced diseases.
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A PPE N D IX  A
Sepharose Standard Curve
1000000




FIG. 25. Standardization o f sepharose CL-6B gel filtration column (52 x 5 cm i.d.). The 
ratio o f  elution volumes (Vc) to the elution volume (V0) o f blue dextran (Mr= 2.000.000) 
were plotted against the molecular weights o f  the standards. Standards: (i-amylase (Mr= 
200.000), alchohol dehydrogenase (Mr= 150.000). albumin (Mr= 66.000. carbonic 
anvhydrase (Mr= 29.000 and cytochrome C (Mr= 12.000)




Summary o f Preliminary Trials with Chromatographic Resins
Resin Technique Problems with Method




inconsistency in results; activity drops 
5-fold each preparation;does not 
consistently appear in Western Blot
phenylsepharose hydrophobic interaction did not stick to co!umn:not much 
cleanennever appeared on Western Blot
DNA cellulose ligand affinity did not appear on Western Blot; activity 
dropped 6-fold
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A PPE N D IX  C
Sequence of the Protease Construct
10 20 30 40 50
A CC  G G G  G G A  G G T  T T A  A A C  T C C  C CC C CC A C A  T T A  CAG C A A  G T C  C T T  C C T  A A C  C A A  
T C C  C C C  C C T  C C A  A A T  T G G  A G G  GGG  G G G  T G T  A A T  GTC G T T  C A G  G A A  G G A  T TG  G T T  
A rg G ly  G ly G lv Leu T h r Ser Pro Pro T hr Leu Gin Gin Val Leu Pro Asn Gin
60 70 80 90 100
G A C  C T A  G C A  T C T  A T T  C TG  CCA  G T T  ATA C C G  T TA  G A T  CCC G C C  C G T  C G G  C CC 
CTG  G A T  C G T  A G A  T A A  G A C  G G T  CAA  TA T G G C  A A T  CTA  GGG C G G  G C A  G CC G G G  
A sp Leu A la S er lie L eu Pro Val lie Pro Leu ’Asp Pro A la A rg  A rg Pro
110 120 130 140 150
G TA  A T T  A A A  G C C  C A G  G T T  G A C  A CC CAG  A C C  A G C  CAC CCA A A G  A C T  A TC G A A  G C T  
C A T  T A A  T T T  C G G  G T C  C A A  C TG  TGG G TC  T G G  TC G  GTG G G T  T T C  T G A  T A G  C T T  C G A  
Val lie  Lys A la G in V al A sp T hr G in T hr S er His Pro Lys T h r He G lu A la
160 170 180 190 200 210
T TA  C T A  G A T  A C A  G G A  G C A  G A C  ATG ACA G T C  C T T  CCA ATA G C C  T T G  TTC  T C A  A T T  
A A T  G A T  C TA  T G T  C C T  C G T  CTG  TA C T G T  C A G  G A A  G G T  TA T  C G G  A A C  A A G  A G T  T T A  
Leu Leu A sp T hr G ly A la  Asp M et T hr Val Leu Pro lie A la Leu Phe Ser Asn
220 230 240 250 260
A A T  A C T  C C C  C T C  A A A  G A C  A CA  TCC G TA  T T G  G G G  GCA GGA  G G C  C A A  A CC C A A  G A T  
T TA  T G A  G G G  G A G  T T T  C T G  T G T  AGG C A T  A A C  C C C  CG T C C T  C C G  G T T  TG G  G T T  C TA  
A sn T h r Pro Leu Lys A sp  T h r Ser Val Leu G ly  A la Gly G ly  G in  T hr G in A sp
270 280 290 300 310 320
C A C  T T T  A A G  C TC  A C C  T C C  C TT  C C T  G TG  C T A  A T A  CGC CTC C C T  T T C  CGG  A C A  A C G  
G TG  A A A  TTC  G A G  T G G  A G G  G A A  G G A  C A C  G A T  T A T  G CG  G AG  G G A  A A G  G CC  T G T  T G C  
His Phe Lys Leu T h r S e r Leu Pro Val Leu lie  A rg Leu Pro Phe A rg T hr T hr
330 340 350 360 370
C C T  A T T  G T T  T TA  A C A  T C T  TG C  CTA G T T  G A T  A C C  AAA AAC A A C  T G G  G C C  A TC  A TA  
G G A  T A A  C A A  A A T  T G T  A G A  A CG  G A T  C A A  C T A  T G G  TTT TTG T T G  A C C  C G G  T A G  T A T  
Pro He Val Leu T hr S e r C ys Leu Val A sp T h r Lys Asn Asn T rp  A la He He
380 390 400 410 420
G G T  C G T  G A T  G C C  T T A  C A A  C A A  TG C C A A  G G C  G T C  CTG TA C C T C  C C T  G A G  G C A  A A A  
C C A  G C A  C T A  C G G  A A T  G T T  G T T  ACG G T T  C C G  C A G  GAC ATG G A G  G G A  CTC C G T  T T T  
G ly A rg  A sp A la  Leu G in  G in C ys Gin G ly Val Leu Tvr Leu P ro  G lu A la Lys
430 440 450 460 470 480
A G G  C C G  C C T  G TA  A T C  T T G  CCA  A TA  CAG  G C G  C C A  G CC G TC C T T  G G C  C T A  G A A  
T C C  G G C  G G A  C A T  T A G  A A C  G G T  T A T  G TC  C G C  G G T  CGG CAG G A A  C C G  G A T  C T T  
A rg Pro  Pro Val He L eu Pro He G in A la Pro A la Val Leu G ly  Leu Glu
FIG. 26. Protease construct created by amplifying the pro ORF from pRCH. Primers 
were chosen to create unique Ndel and Bam HI sites to allow subsequent cloning in 
frame with the N-terminal His tag coding sequence.
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Fig. 29. MS analysis o f Peptide 3 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
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Fig. 31. MS analysis of Peptide 5 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
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Fig. 33. MS analysis of Peptide latter tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
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